US20120269864A1 - Arginine Derivatives with NP-I Antagonistic Activity - Google Patents
Arginine Derivatives with NP-I Antagonistic Activity Download PDFInfo
- Publication number
- US20120269864A1 US20120269864A1 US13/493,110 US201213493110A US2012269864A1 US 20120269864 A1 US20120269864 A1 US 20120269864A1 US 201213493110 A US201213493110 A US 201213493110A US 2012269864 A1 US2012269864 A1 US 2012269864A1
- Authority
- US
- United States
- Prior art keywords
- amino
- guanidino
- carbonyl
- thiophene
- pentanoic acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 [1*]N/C(CCCCC(NC(=O)C[Y]CC)C(C)=O)=N/C.[1*]N/C(CCCCN(CC(C)=O)C(=O)C[Y]CC)=N/C Chemical compound [1*]N/C(CCCCC(NC(=O)C[Y]CC)C(C)=O)=N/C.[1*]N/C(CCCCN(CC(C)=O)C(=O)C[Y]CC)=N/C 0.000 description 25
- ZERSSBOWPZLDRJ-MERQFXBCSA-N C.CC(C)(C)N[C@@H](CCCCC(=N)N)C(=O)C(C)(C)C Chemical compound C.CC(C)(C)N[C@@H](CCCCC(=N)N)C(=O)C(C)(C)C ZERSSBOWPZLDRJ-MERQFXBCSA-N 0.000 description 3
- SEDDZUBHXNXTAH-CQSZACIVSA-N COC(=O)[C@H](CCC(=O)OC(C)(C)C)CC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1 Chemical compound COC(=O)[C@H](CCC(=O)OC(C)(C)C)CC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1 SEDDZUBHXNXTAH-CQSZACIVSA-N 0.000 description 2
- CREMABGTGYGIQB-UHFFFAOYSA-N C.C Chemical compound C.C CREMABGTGYGIQB-UHFFFAOYSA-N 0.000 description 1
- FEAAJVCCWPXGFU-UHFFFAOYSA-N C.CC(C)(C)OC(=O)C(C)(C)C Chemical compound C.CC(C)(C)OC(=O)C(C)(C)C FEAAJVCCWPXGFU-UHFFFAOYSA-N 0.000 description 1
- DMRUCQLJCKZBRT-UHFFFAOYSA-N C.CC1=C2CC(C)(C)OC2=C(C)C(C)=C1S(=O)(=O)C(C)(C)C Chemical compound C.CC1=C2CC(C)(C)OC2=C(C)C(C)=C1S(=O)(=O)C(C)(C)C DMRUCQLJCKZBRT-UHFFFAOYSA-N 0.000 description 1
- YFWPPLNBRFNBNN-UHFFFAOYSA-N CBr.CC.CC1=C(C)C(S(=O)(=O)NC2=C(C(=O)O)SC=C2)=CC=C1.CC1=C(C)C(S(=O)(=O)NC2=C(C(=O)O)SC=C2)=CC=C1 Chemical compound CBr.CC.CC1=C(C)C(S(=O)(=O)NC2=C(C(=O)O)SC=C2)=CC=C1.CC1=C(C)C(S(=O)(=O)NC2=C(C(=O)O)SC=C2)=CC=C1 YFWPPLNBRFNBNN-UHFFFAOYSA-N 0.000 description 1
- BBGUHCIDOOUTQQ-CQSZACIVSA-N CC(=N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)OC(C)(C)C Chemical compound CC(=N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)OC(C)(C)C BBGUHCIDOOUTQQ-CQSZACIVSA-N 0.000 description 1
- PJBULBMCBDSIPJ-RFVHGSKJSA-N CC(=O)C1=C(NS(=O)(=O)C2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2)C=CS1.N=C(N)NCCC[C@H](CC(=O)C1=C(NS(=O)(=O)C2=CC(B(O)O)=CC=C2)C=CS1)C(=O)O Chemical compound CC(=O)C1=C(NS(=O)(=O)C2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2)C=CS1.N=C(N)NCCC[C@H](CC(=O)C1=C(NS(=O)(=O)C2=CC(B(O)O)=CC=C2)C=CS1)C(=O)O PJBULBMCBDSIPJ-RFVHGSKJSA-N 0.000 description 1
- ZYFSZHCRNZKZLL-UHFFFAOYSA-N CC(=O)C1=CC=C(C2=CC=C(N)C=C2)C=C1.CCCCCCC(=O)NC1=CC=C(C2=CC=C(C(C)=O)C=C2)C=C1 Chemical compound CC(=O)C1=CC=C(C2=CC=C(N)C=C2)C=C1.CCCCCCC(=O)NC1=CC=C(C2=CC=C(C(C)=O)C=C2)C=C1 ZYFSZHCRNZKZLL-UHFFFAOYSA-N 0.000 description 1
- OVVGCLNBWLKJMX-INIZCTEOSA-N CC(=O)CC1=CC=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=C1 Chemical compound CC(=O)CC1=CC=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=C1 OVVGCLNBWLKJMX-INIZCTEOSA-N 0.000 description 1
- LYDHDHSKJXRTCM-JTQLQIEISA-N CC(C)(C)C([C@H](CCCNC(N)=N)NC(C)(C)C)=O Chemical compound CC(C)(C)C([C@H](CCCNC(N)=N)NC(C)(C)C)=O LYDHDHSKJXRTCM-JTQLQIEISA-N 0.000 description 1
- NMFBFVLPXRDEIU-VMIGMULUSA-N CC(C)(C)OC(=O)C(C)(C)C.CC(C)(C)OC(=O)NC(=N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)OC(C)(C)C.N=C(N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)O Chemical compound CC(C)(C)OC(=O)C(C)(C)C.CC(C)(C)OC(=O)NC(=N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)OC(C)(C)C.N=C(N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)O NMFBFVLPXRDEIU-VMIGMULUSA-N 0.000 description 1
- TVPPTNKKEMUJBE-NRQJTAIJSA-N CC(C)(C)OC(=O)C(C)(C)C.COC(=O)[C@H](CCC(=O)NC(=N)NC(=O)OC(C)(C)C)CC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1.N=C(N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1)C(=O)O Chemical compound CC(C)(C)OC(=O)C(C)(C)C.COC(=O)[C@H](CCC(=O)NC(=N)NC(=O)OC(C)(C)C)CC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1.N=C(N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1)C(=O)O TVPPTNKKEMUJBE-NRQJTAIJSA-N 0.000 description 1
- IJRJSMHUZJIIGA-VFQONQGVSA-N CC(C)(C)OC(=O)C(C)(C)C.COC(=O)[C@H](CCC(=O)NC(C)=N)CC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1.N=C(N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1)C(=O)O Chemical compound CC(C)(C)OC(=O)C(C)(C)C.COC(=O)[C@H](CCC(=O)NC(C)=N)CC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1.N=C(N)NC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1)C(=O)O IJRJSMHUZJIIGA-VFQONQGVSA-N 0.000 description 1
- GZZJQRCFQKAOTB-UHFFFAOYSA-N CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2)C=CS1 Chemical compound CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC(B3OC(C)(C)C(C)(C)O3)=CC=C2)C=CS1 GZZJQRCFQKAOTB-UHFFFAOYSA-N 0.000 description 1
- TVKXTGYQDLISDY-UHFFFAOYSA-N CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=NC=C3)=CC=C2)C=CS1 Chemical compound CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=NC=C3)=CC=C2)C=CS1 TVKXTGYQDLISDY-UHFFFAOYSA-N 0.000 description 1
- IGNLDYLXSOLQKX-UHFFFAOYSA-N CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC(C3=C\C=C4\OCC\C4=C\3)=CC=C2)C=CS1 Chemical compound CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC(C3=C\C=C4\OCC\C4=C\3)=CC=C2)C=CS1 IGNLDYLXSOLQKX-UHFFFAOYSA-N 0.000 description 1
- ONYUTDGLBQMVDN-UHFFFAOYSA-N CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CC=NC=C2)C=CS1 Chemical compound CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CC=NC=C2)C=CS1 ONYUTDGLBQMVDN-UHFFFAOYSA-N 0.000 description 1
- ZZEJSAKPMLXJSN-UHFFFAOYSA-N CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CN=CN=C2)C=CS1 Chemical compound CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CN=CN=C2)C=CS1 ZZEJSAKPMLXJSN-UHFFFAOYSA-N 0.000 description 1
- BIQKTIXCVAGMEZ-UHFFFAOYSA-N CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=C\C=C3\OCC\C3=C\2)C=CS1 Chemical compound CC(C)(C)OCC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=C\C=C3\OCC\C3=C\2)C=CS1 BIQKTIXCVAGMEZ-UHFFFAOYSA-N 0.000 description 1
- FGKIMHRKSSCAKL-UHFFFAOYSA-N CC(C)=O.CC(C)=O.CN.CNC(N)=O Chemical compound CC(C)=O.CC(C)=O.CN.CNC(N)=O FGKIMHRKSSCAKL-UHFFFAOYSA-N 0.000 description 1
- NTDMVGYOVFLZJX-UHFFFAOYSA-N CC(C)=O.CC(C)=O.CN.C[N+](=O)[O-] Chemical compound CC(C)=O.CC(C)=O.CN.C[N+](=O)[O-] NTDMVGYOVFLZJX-UHFFFAOYSA-N 0.000 description 1
- HBWPWDYLIKYKIU-LBPRGKRZSA-N CC1=C(C)C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)S1 Chemical compound CC1=C(C)C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)S1 HBWPWDYLIKYKIU-LBPRGKRZSA-N 0.000 description 1
- LCIFZNIRQHRMGP-ZDUSSCGKSA-N CC1=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C(C#N)=CC=C1 Chemical compound CC1=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C(C#N)=CC=C1 LCIFZNIRQHRMGP-ZDUSSCGKSA-N 0.000 description 1
- HNOCLDLFGYADGN-HNNXBMFYSA-N CC1=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C(C2=CC=CC=C2)=NO1 Chemical compound CC1=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C(C2=CC=CC=C2)=NO1 HNOCLDLFGYADGN-HNNXBMFYSA-N 0.000 description 1
- FIOUESKXSHQGFK-NSHDSACASA-N CC1=C(\S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C2=NSN=C2/C=C\1 Chemical compound CC1=C(\S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C2=NSN=C2/C=C\1 FIOUESKXSHQGFK-NSHDSACASA-N 0.000 description 1
- KPZVWRYGPJYLSX-IBGZPJMESA-N CC1=CC(CCC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=NN1C Chemical compound CC1=CC(CCC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=NN1C KPZVWRYGPJYLSX-IBGZPJMESA-N 0.000 description 1
- SEMSSOIZPYDLNT-SFHVURJKSA-N CC1=CC(CCC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=NO1 Chemical compound CC1=CC(CCC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=NO1 SEMSSOIZPYDLNT-SFHVURJKSA-N 0.000 description 1
- CWNVNBJMIREKHF-AWEZNQCLSA-N CC1=CC=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=C1 Chemical compound CC1=CC=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=C1 CWNVNBJMIREKHF-AWEZNQCLSA-N 0.000 description 1
- IRUIGWLQPKYOIZ-KRWDZBQOSA-N CC1=NC(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=CC=N1 Chemical compound CC1=NC(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=CC=N1 IRUIGWLQPKYOIZ-KRWDZBQOSA-N 0.000 description 1
- XCMVTNPCHPDQBH-HNNXBMFYSA-N CC1=NC(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)=NO1 Chemical compound CC1=NC(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)=NO1 XCMVTNPCHPDQBH-HNNXBMFYSA-N 0.000 description 1
- UYNJDBFPGWMHFZ-FQEVSTJZSA-N CC1=NC(CCC2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)=C(C)O1 Chemical compound CC1=NC(CCC2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)=C(C)O1 UYNJDBFPGWMHFZ-FQEVSTJZSA-N 0.000 description 1
- JGRJIKNIFMKOFE-KRWDZBQOSA-N CC1=NC(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=C(C)O1 Chemical compound CC1=NC(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)=C(C)O1 JGRJIKNIFMKOFE-KRWDZBQOSA-N 0.000 description 1
- MDQHXNDASUOTMR-KRWDZBQOSA-N CC1=NC(CNC2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C(C)O1 Chemical compound CC1=NC(CNC2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C(C)O1 MDQHXNDASUOTMR-KRWDZBQOSA-N 0.000 description 1
- GRGNMCKJQJAXKY-NSHDSACASA-N CC1=NC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=CN1C Chemical compound CC1=NC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=CN1C GRGNMCKJQJAXKY-NSHDSACASA-N 0.000 description 1
- AISRRDUYJFZQAE-UHFFFAOYSA-N CC1=NC=C(C2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)C=N1 Chemical compound CC1=NC=C(C2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)C=N1 AISRRDUYJFZQAE-UHFFFAOYSA-N 0.000 description 1
- KSCIMERSRITCFS-NRFANRHFSA-N CC1=NN(C)C(C)=C1CCC(=O)C1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 Chemical compound CC1=NN(C)C(C)=C1CCC(=O)C1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 KSCIMERSRITCFS-NRFANRHFSA-N 0.000 description 1
- NPRWPRNANUHVRK-FQEVSTJZSA-N CC1=NN(C)C(CCC2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)=C1 Chemical compound CC1=NN(C)C(CCC2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)=C1 NPRWPRNANUHVRK-FQEVSTJZSA-N 0.000 description 1
- FVADIWDDVDCHMM-IBGZPJMESA-N CC1=NN(C)C(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)=C1 Chemical compound CC1=NN(C)C(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)=C1 FVADIWDDVDCHMM-IBGZPJMESA-N 0.000 description 1
- PFHNOGPWKPEYKW-SFHVURJKSA-N CC1=NN(C)C(Cl)=C1CCC1=CC=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C=C1 Chemical compound CC1=NN(C)C(Cl)=C1CCC1=CC=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C=C1 PFHNOGPWKPEYKW-SFHVURJKSA-N 0.000 description 1
- FOYHTZQRCFVQSQ-SFHVURJKSA-N CC1=NN(C)C(Cl)=C1CNC1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 Chemical compound CC1=NN(C)C(Cl)=C1CNC1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 FOYHTZQRCFVQSQ-SFHVURJKSA-N 0.000 description 1
- ASCILABSHQJRGU-QHCPKHFHSA-N CC1=NN(C2=CC=CC=C2)C(Cl)=C1CNC1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 Chemical compound CC1=NN(C2=CC=CC=C2)C(Cl)=C1CNC1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 ASCILABSHQJRGU-QHCPKHFHSA-N 0.000 description 1
- FSAWWIQEPVTNLB-NRFANRHFSA-N CC1=NN(C2=CC=CC=C2)C(Cl)=C1CNC1=CC=CC=C1S(=O)(=O)NC1=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C1 Chemical compound CC1=NN(C2=CC=CC=C2)C(Cl)=C1CNC1=CC=CC=C1S(=O)(=O)NC1=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C1 FSAWWIQEPVTNLB-NRFANRHFSA-N 0.000 description 1
- XSYKSCTUYQYOID-UHFFFAOYSA-N CC1=NOC(C)=C1C1=C/C2=C(OCC2)/C(S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)=C\1 Chemical compound CC1=NOC(C)=C1C1=C/C2=C(OCC2)/C(S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)=C\1 XSYKSCTUYQYOID-UHFFFAOYSA-N 0.000 description 1
- LDCULLBSKYKSCU-KRWDZBQOSA-N CC1=NOC(C)=C1C1=C/C2=C(OCC2)/C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C\1 Chemical compound CC1=NOC(C)=C1C1=C/C2=C(OCC2)/C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C\1 LDCULLBSKYKSCU-KRWDZBQOSA-N 0.000 description 1
- WBHBXCDUQCINIQ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC=C(S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)C=C1 Chemical compound CC1=NOC(C)=C1C1=CC=C(S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)C=C1 WBHBXCDUQCINIQ-UHFFFAOYSA-N 0.000 description 1
- JYOUXHRFWHIDPS-KRWDZBQOSA-N CC1=NOC(C)=C1C1=CC=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=C1 Chemical compound CC1=NOC(C)=C1C1=CC=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=C1 JYOUXHRFWHIDPS-KRWDZBQOSA-N 0.000 description 1
- KMSFHYJQYQWFOZ-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC=CC(S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)=C1 Chemical compound CC1=NOC(C)=C1C1=CC=CC(S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)=C1 KMSFHYJQYQWFOZ-UHFFFAOYSA-N 0.000 description 1
- QVHMMJRMSNGYQR-KRWDZBQOSA-N CC1=NOC(C)=C1C1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 Chemical compound CC1=NOC(C)=C1C1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 QVHMMJRMSNGYQR-KRWDZBQOSA-N 0.000 description 1
- LFKZIXZWHSLJKK-UHFFFAOYSA-N CC1=NOC(C)=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C(=O)COC(C)(C)C)SC=C1 Chemical compound CC1=NOC(C)=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C(=O)COC(C)(C)C)SC=C1 LFKZIXZWHSLJKK-UHFFFAOYSA-N 0.000 description 1
- WOCBDOLHSKMHNM-INIZCTEOSA-N CC1=NOC(C)=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C1 Chemical compound CC1=NOC(C)=C1C1=CC=CC=C1S(=O)(=O)NC1=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C1 WOCBDOLHSKMHNM-INIZCTEOSA-N 0.000 description 1
- JTMQPAJJKPXMMZ-IBGZPJMESA-N CC1=NOC(C)=C1CCC1=CC=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C=C1 Chemical compound CC1=NOC(C)=C1CCC1=CC=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)C=C1 JTMQPAJJKPXMMZ-IBGZPJMESA-N 0.000 description 1
- AKKDGZQLBXKNRI-SFHVURJKSA-N CC1=NOC(C)=C1CNC1=CC=CC(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)=C1 Chemical compound CC1=NOC(C)=C1CNC1=CC=CC(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)=C1 AKKDGZQLBXKNRI-SFHVURJKSA-N 0.000 description 1
- AROBYNFWBNLXHS-UHFFFAOYSA-N CN1C=C(C2=C/C3=C(OCC3)/C(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)=C\2)C=N1 Chemical compound CN1C=C(C2=C/C3=C(OCC3)/C(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)=C\2)C=N1 AROBYNFWBNLXHS-UHFFFAOYSA-N 0.000 description 1
- VTGHKHZQWDFAOQ-KRWDZBQOSA-N CN1C=C(C2=C/C3=C(OCC3)/C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C\2)C=N1 Chemical compound CN1C=C(C2=C/C3=C(OCC3)/C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C\2)C=N1 VTGHKHZQWDFAOQ-KRWDZBQOSA-N 0.000 description 1
- LENATURRVJQMBI-UHFFFAOYSA-N CN1C=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)C=C2)C=N1 Chemical compound CN1C=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)C=C2)C=N1 LENATURRVJQMBI-UHFFFAOYSA-N 0.000 description 1
- AGMNAJXIXBRFAV-KRWDZBQOSA-N CN1C=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)C=N1 Chemical compound CN1C=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)C=N1 AGMNAJXIXBRFAV-KRWDZBQOSA-N 0.000 description 1
- HYKFPCIGASDPLX-UHFFFAOYSA-N CN1C=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)=C2)C=N1 Chemical compound CN1C=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)=C2)C=N1 HYKFPCIGASDPLX-UHFFFAOYSA-N 0.000 description 1
- AUNFCAWJKVMDCB-KRWDZBQOSA-N CN1C=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=N1 Chemical compound CN1C=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=N1 AUNFCAWJKVMDCB-KRWDZBQOSA-N 0.000 description 1
- JLYGCTLFFJEBND-UHFFFAOYSA-N CN1C=C(C2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)C=N1 Chemical compound CN1C=C(C2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)COC(C)(C)C)SC=C2)C=N1 JLYGCTLFFJEBND-UHFFFAOYSA-N 0.000 description 1
- GBTMBZNPGLEVNF-INIZCTEOSA-N CN1C=C(C2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=N1 Chemical compound CN1C=C(C2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=N1 GBTMBZNPGLEVNF-INIZCTEOSA-N 0.000 description 1
- XRGBYEOGNRKILD-HNNXBMFYSA-N CN1C=C(Cl)C(CNC2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)=N1 Chemical compound CN1C=C(Cl)C(CNC2=CC=CC=C2S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C2)=N1 XRGBYEOGNRKILD-HNNXBMFYSA-N 0.000 description 1
- CBSAMTQCNLKXEE-SFHVURJKSA-N CN1C=CC(CC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)=N1 Chemical compound CN1C=CC(CC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)=N1 CBSAMTQCNLKXEE-SFHVURJKSA-N 0.000 description 1
- CXPDKOUZRRYSCQ-IBGZPJMESA-N CN1C=NC=C1C#CC1=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=CC=C1 Chemical compound CN1C=NC=C1C#CC1=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=CC=C1 CXPDKOUZRRYSCQ-IBGZPJMESA-N 0.000 description 1
- LZQRPQKNOZYMEI-AWEZNQCLSA-N CN1CCOC2=C1C=CC(S(=O)(=O)NC1=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C1)=C2 Chemical compound CN1CCOC2=C1C=CC(S(=O)(=O)NC1=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C1)=C2 LZQRPQKNOZYMEI-AWEZNQCLSA-N 0.000 description 1
- RKSWMZXMPLXEPS-UHFFFAOYSA-N CN1CCOC2=CC(C3=C/C4=C(OCC4)/C(S(=O)(=O)NC4=C(C(=O)COC(C)(C)C)SC=C4)=C\3)=CN=C21 Chemical compound CN1CCOC2=CC(C3=C/C4=C(OCC4)/C(S(=O)(=O)NC4=C(C(=O)COC(C)(C)C)SC=C4)=C\3)=CN=C21 RKSWMZXMPLXEPS-UHFFFAOYSA-N 0.000 description 1
- AXMFZQACRWUYHE-IBGZPJMESA-N CN1CCOC2=CC(C3=C/C4=C(OCC4)/C(S(=O)(=O)NC4=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C4)=C\3)=CN=C21 Chemical compound CN1CCOC2=CC(C3=C/C4=C(OCC4)/C(S(=O)(=O)NC4=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C4)=C\3)=CN=C21 AXMFZQACRWUYHE-IBGZPJMESA-N 0.000 description 1
- ILXFFQSMFVEUBQ-IBGZPJMESA-N CN1N=C(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)C2=CC=CC=C21 Chemical compound CN1N=C(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)C2=CC=CC=C21 ILXFFQSMFVEUBQ-IBGZPJMESA-N 0.000 description 1
- XJPADRBAHOCSAA-FQEVSTJZSA-N CN1N=C(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=C1C1=CC=CO1 Chemical compound CN1N=C(CNC2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=C1C1=CC=CO1 XJPADRBAHOCSAA-FQEVSTJZSA-N 0.000 description 1
- VHCXXTUKRIHLKI-CYBMUJFWSA-N COC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)OC(C)(C)C Chemical compound COC(=O)CC[C@H](CC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)OC(C)(C)C VHCXXTUKRIHLKI-CYBMUJFWSA-N 0.000 description 1
- YARHOESSKZPODG-CYBMUJFWSA-N COC(=O)[C@H](CCC(=O)NC(C)=N)CC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1 Chemical compound COC(=O)[C@H](CCC(=O)NC(C)=N)CC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1 YARHOESSKZPODG-CYBMUJFWSA-N 0.000 description 1
- GXWFJFVVLHHQPV-LBPRGKRZSA-N COC1=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=CC(Br)=C1 Chemical compound COC1=C(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)C=CC(Br)=C1 GXWFJFVVLHHQPV-LBPRGKRZSA-N 0.000 description 1
- QCQCVPMUKJMBGO-CQQBXOTJSA-N COC1=CC=C(/C=C/C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)C=C1 Chemical compound COC1=CC=C(/C=C/C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)C=C1 QCQCVPMUKJMBGO-CQQBXOTJSA-N 0.000 description 1
- HBPPSRMHLTWUHA-NRFANRHFSA-N COC1=CC=C(C(=O)CC2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=C1 Chemical compound COC1=CC=C(C(=O)CC2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=C1 HBPPSRMHLTWUHA-NRFANRHFSA-N 0.000 description 1
- MKACVVCTFRVMHX-IBGZPJMESA-N COC1=CC=C(CC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)C=C1OC Chemical compound COC1=CC=C(CC(=O)C2=CC=CC(S(=O)(=O)NC3=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C3)=C2)C=C1OC MKACVVCTFRVMHX-IBGZPJMESA-N 0.000 description 1
- CEQCFKXLWGMKDB-HNNXBMFYSA-N COC1=CC=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC(C(C)(C)C)=C2)C=C1 Chemical compound COC1=CC=C(S(=O)(=O)NC2=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC(C(C)(C)C)=C2)C=C1 CEQCFKXLWGMKDB-HNNXBMFYSA-N 0.000 description 1
- NUSQIDYRTWJSCX-UHFFFAOYSA-N COC1=NC=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)C=C2)C=N1 Chemical compound COC1=NC=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)C=C2)C=N1 NUSQIDYRTWJSCX-UHFFFAOYSA-N 0.000 description 1
- OZDXWPPOXVTODS-KRWDZBQOSA-N COC1=NC=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)C=N1 Chemical compound COC1=NC=C(C2=CC=C(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)C=C2)C=N1 OZDXWPPOXVTODS-KRWDZBQOSA-N 0.000 description 1
- KQIPPOMSWLFBCA-UHFFFAOYSA-N COC1=NC=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)=C2)C=N1 Chemical compound COC1=NC=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)COC(C)(C)C)SC=C3)=C2)C=N1 KQIPPOMSWLFBCA-UHFFFAOYSA-N 0.000 description 1
- ZLCBJQBCLKNCRO-KRWDZBQOSA-N COC1=NC=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=N1 Chemical compound COC1=NC=C(C2=CC=CC(S(=O)(=O)NC3=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C3)=C2)C=N1 ZLCBJQBCLKNCRO-KRWDZBQOSA-N 0.000 description 1
- NDXQFEBMHGWUNZ-SFHVURJKSA-N COCCCCC(=O)C1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 Chemical compound COCCCCC(=O)C1=CC=CC(S(=O)(=O)NC2=C(C(=O)N[C@@H](CCCNC(=N)N)C(=O)O)SC=C2)=C1 NDXQFEBMHGWUNZ-SFHVURJKSA-N 0.000 description 1
- LLSNLPPYUWINIF-ZETCQYMHSA-N CS(=O)(=O)NC1=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C1 Chemical compound CS(=O)(=O)NC1=C(C(=O)C(=O)[C@H](CCCNC(=N)N)NO)SC=C1 LLSNLPPYUWINIF-ZETCQYMHSA-N 0.000 description 1
- FKVUFDNRHIQBCT-BSGLVDAKSA-N N=C(N)NCCC[C@H](CC(=O)C1=C(CS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)NO.N=C(N)NCCC[C@H](CC(=O)C1=C(CS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](CC(=O)C1=C(CS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)NO.N=C(N)NCCC[C@H](CC(=O)C1=C(CS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)O FKVUFDNRHIQBCT-BSGLVDAKSA-N 0.000 description 1
- UTZPWUVEAONIOC-ZDUSSCGKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)/C2=C/C(Br)=C\C3=C2OCC3)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)/C2=C/C(Br)=C\C3=C2OCC3)C=CS1)C(=O)O UTZPWUVEAONIOC-ZDUSSCGKSA-N 0.000 description 1
- CMLDDMZTIAQFMW-NSHDSACASA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NON=C32)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NON=C32)C=CS1)C(=O)O CMLDDMZTIAQFMW-NSHDSACASA-N 0.000 description 1
- ZWWMEDURALZMEV-NSHDSACASA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)/C2=C/C=C\C3=NSN=C32)C=CS1)C(=O)O ZWWMEDURALZMEV-NSHDSACASA-N 0.000 description 1
- OHKCMSAHLFSLJA-LBPRGKRZSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=C(F)C=C(F)C=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=C(F)C=C(F)C=C2)C=CS1)C(=O)O OHKCMSAHLFSLJA-LBPRGKRZSA-N 0.000 description 1
- OIVJCTMOEROGSB-HNNXBMFYSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=C([N+](=O)[O-])C=CC=C2)C=C(C2=CC=CC=C2)S1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=C([N+](=O)[O-])C=CC=C2)C=C(C2=CC=CC=C2)S1)C(=O)O OIVJCTMOEROGSB-HNNXBMFYSA-N 0.000 description 1
- IXMFJHHRCNZIGL-LBPRGKRZSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=C/C3=NSN=C3/C=C\2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=C/C3=NSN=C3/C=C\2)C=CS1)C(=O)O IXMFJHHRCNZIGL-LBPRGKRZSA-N 0.000 description 1
- RWHJROYVPRNXQH-SFHVURJKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C(=O)CCCCCN)=CC=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C(=O)CCCCCN)=CC=C2)C=CS1)C(=O)O RWHJROYVPRNXQH-SFHVURJKSA-N 0.000 description 1
- MVFPKXCTKPUYTB-INIZCTEOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C(=O)CCCN)=CC=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C(=O)CCCN)=CC=C2)C=CS1)C(=O)O MVFPKXCTKPUYTB-INIZCTEOSA-N 0.000 description 1
- CPEQNKYNPDQDIV-INIZCTEOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=CS3)=CC=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=CS3)=CC=C2)C=CS1)C(=O)O CPEQNKYNPDQDIV-INIZCTEOSA-N 0.000 description 1
- QRVSDGKRCRUNFQ-SFHVURJKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=NC=C3)=CC=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=NC=C3)=CC=C2)C=CS1)C(=O)O QRVSDGKRCRUNFQ-SFHVURJKSA-N 0.000 description 1
- YHYXLGJSTSSVOJ-KRWDZBQOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CN=CN=C3)=CC=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(C3=CN=CN=C3)=CC=C2)C=CS1)C(=O)O YHYXLGJSTSSVOJ-KRWDZBQOSA-N 0.000 description 1
- CDPTVBRXBDKYQV-IBGZPJMESA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(NCC3=CC=CC=N3)=CC=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC(NCC3=CC=CC=N3)=CC=C2)C=CS1)C(=O)O CDPTVBRXBDKYQV-IBGZPJMESA-N 0.000 description 1
- JNGYRNNUBUZZMR-ZDUSSCGKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC3=C(C=CC=C3)S2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC3=C(C=CC=C3)S2)C=CS1)C(=O)O JNGYRNNUBUZZMR-ZDUSSCGKSA-N 0.000 description 1
- IUMROXUBUGSCQW-ZDUSSCGKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(Br)C=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(Br)C=C2)C=CS1)C(=O)O IUMROXUBUGSCQW-ZDUSSCGKSA-N 0.000 description 1
- OPNYZAQXJRWBCQ-AWEZNQCLSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(C3=NC=CC=C3)S2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(C3=NC=CC=C3)S2)C=CS1)C(=O)O OPNYZAQXJRWBCQ-AWEZNQCLSA-N 0.000 description 1
- UQKKFSVNOWLRKT-INIZCTEOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=CC=C1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=CC=C1)C(=O)O UQKKFSVNOWLRKT-INIZCTEOSA-N 0.000 description 1
- RMKAQDLTOCVNHK-ZDUSSCGKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(N)C=C2)C=CS1)C(=O)O RMKAQDLTOCVNHK-ZDUSSCGKSA-N 0.000 description 1
- WVSZBMDJPYIDIW-KRWDZBQOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(OC3=CC=CC=C3)N=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C(OC3=CC=CC=C3)N=C2)C=CS1)C(=O)O WVSZBMDJPYIDIW-KRWDZBQOSA-N 0.000 description 1
- BRHWBVXFXBEJOE-ZDUSSCGKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=C([N+](=O)[O-])C=C2)C=CS1)C(=O)O BRHWBVXFXBEJOE-ZDUSSCGKSA-N 0.000 description 1
- YHZUGKPJRWTJDB-INIZCTEOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC3=CC=CC=C32)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC3=CC=CC=C32)C=CS1)C(=O)O YHZUGKPJRWTJDB-INIZCTEOSA-N 0.000 description 1
- NZYKVSQEEKVFBQ-ZDUSSCGKSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2)SC=C1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2)SC=C1)C(=O)O NZYKVSQEEKVFBQ-ZDUSSCGKSA-N 0.000 description 1
- WXUPBBLCKPJFDM-KRWDZBQOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CC=NC=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CC=NC=C2)C=CS1)C(=O)O WXUPBBLCKPJFDM-KRWDZBQOSA-N 0.000 description 1
- PIOCJCFIPLBYMU-INIZCTEOSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CN=CN=C2)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2C2=CN=CN=C2)C=CS1)C(=O)O PIOCJCFIPLBYMU-INIZCTEOSA-N 0.000 description 1
- YRDXVLQHXGUFAO-LBPRGKRZSA-N N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2N)C=CS1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2N)C=CS1)C(=O)O YRDXVLQHXGUFAO-LBPRGKRZSA-N 0.000 description 1
- ZIJVQPWDSDRAOJ-KRWDZBQOSA-N N=C(N)NCCC[C@H](NC(=O)C1=CC(NC(=O)C2=CC=C(CN)C=C2)=CC=C1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=CC(NC(=O)C2=CC=C(CN)C=C2)=CC=C1)C(=O)O ZIJVQPWDSDRAOJ-KRWDZBQOSA-N 0.000 description 1
- CBSQWQZEZFAHHL-INIZCTEOSA-N N=C(N)NCCC[C@H](NC(=O)C1=CC(NS(=O)(=O)C2=CC=CC(N)=C2)=CC=C1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=CC(NS(=O)(=O)C2=CC=CC(N)=C2)=CC=C1)C(=O)O CBSQWQZEZFAHHL-INIZCTEOSA-N 0.000 description 1
- RNBALCQFVOERKF-FQEVSTJZSA-N N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=C(NC(=O)CCCCN)C=C2)C=C1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=C(NC(=O)CCCCN)C=C2)C=C1)C(=O)O RNBALCQFVOERKF-FQEVSTJZSA-N 0.000 description 1
- SWIROICVICLTPU-IBGZPJMESA-N N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=CC(CS(=O)(=O)C3=CC=C(N)C=C3)=C2)O1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=CC(CS(=O)(=O)C3=CC=C(N)C=C3)=C2)O1)C(=O)O SWIROICVICLTPU-IBGZPJMESA-N 0.000 description 1
- RVXDAOUCBVLTHX-LBPRGKRZSA-N N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=CC(N)=C2)O1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=CC(N)=C2)O1)C(=O)O RVXDAOUCBVLTHX-LBPRGKRZSA-N 0.000 description 1
- AACVZQJWVCGWPD-SFHVURJKSA-N N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=CC=C2NS(=O)(=O)C2=CC=CC(N)=C2)O1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=CC=C(C2=CC=CC=C2NS(=O)(=O)C2=CC=CC(N)=C2)O1)C(=O)O AACVZQJWVCGWPD-SFHVURJKSA-N 0.000 description 1
- GINFBXHXZSTWLY-NSHDSACASA-N N=C(N)NCCC[C@H](NC(=O)C1=CSC(NS(=O)(=O)C2=CC=CC(N)=C2)=N1)C(=O)O Chemical compound N=C(N)NCCC[C@H](NC(=O)C1=CSC(NS(=O)(=O)C2=CC=CC(N)=C2)=N1)C(=O)O GINFBXHXZSTWLY-NSHDSACASA-N 0.000 description 1
- PIBIUUIUWYTAFA-NSHDSACASA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C(Cl)C=C(Cl)C(Cl)=C2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C(Cl)C=C(Cl)C(Cl)=C2)C=CS1 PIBIUUIUWYTAFA-NSHDSACASA-N 0.000 description 1
- MQPGSZILABBEQR-HNNXBMFYSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C([N+](=O)[O-])C=CC=C2)C=C(C2=CC=C([N+](=O)[O-])C=C2)S1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C([N+](=O)[O-])C=CC=C2)C=C(C2=CC=C([N+](=O)[O-])C=C2)S1 MQPGSZILABBEQR-HNNXBMFYSA-N 0.000 description 1
- BGLNALWLHDLNJJ-ZDUSSCGKSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C/C3=C(\C=C/2)OCC3)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C/C3=C(\C=C/2)OCC3)C=CS1 BGLNALWLHDLNJJ-ZDUSSCGKSA-N 0.000 description 1
- USOVSPVTNJESAQ-NSHDSACASA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C/C=C3/OCO/C3=C\2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=C/C=C3/OCO/C3=C\2)C=CS1 USOVSPVTNJESAQ-NSHDSACASA-N 0.000 description 1
- NFPHSGYNXSLVOX-IBGZPJMESA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(C#CC3=CC=CN=C3)=CC=C2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(C#CC3=CC=CN=C3)=CC=C2)C=CS1 NFPHSGYNXSLVOX-IBGZPJMESA-N 0.000 description 1
- ULCFGKLURGTTGT-HNNXBMFYSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(C#CCN)=CC=C2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(C#CCN)=CC=C2)C=CS1 ULCFGKLURGTTGT-HNNXBMFYSA-N 0.000 description 1
- LHTZXYCKCNZFLF-HNNXBMFYSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=CO3)=CC=C2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(C3=CC=CO3)=CC=C2)C=CS1 LHTZXYCKCNZFLF-HNNXBMFYSA-N 0.000 description 1
- GTPFJGVNHSSZLV-INIZCTEOSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(N)=CC=C2)C=CC=C1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(N)=CC=C2)C=CC=C1 GTPFJGVNHSSZLV-INIZCTEOSA-N 0.000 description 1
- QVCGBXJIRIKVNG-LBPRGKRZSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(N)=CC=C2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(N)=CC=C2)C=CS1 QVCGBXJIRIKVNG-LBPRGKRZSA-N 0.000 description 1
- FHBDPBJJWSKAJO-FQEVSTJZSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(NCC3=CC=C(C4=CSN=N4)C=C3)=CC=C2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC(NCC3=CC=C(C4=CSN=N4)C=C3)=CC=C2)C=CS1 FHBDPBJJWSKAJO-FQEVSTJZSA-N 0.000 description 1
- UCNOWTWOZPFEFD-LBPRGKRZSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC3=C(C=CC=C3)O2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC3=C(C=CC=C3)O2)C=CS1 UCNOWTWOZPFEFD-LBPRGKRZSA-N 0.000 description 1
- QQCSADGBBBSYSC-JTQLQIEISA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC=C(C3=CN=CO3)S2)C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC=C(C3=CN=CO3)S2)C=CS1 QQCSADGBBBSYSC-JTQLQIEISA-N 0.000 description 1
- GGEBRAOZEQLQSI-AWEZNQCLSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC=CC3=NSN=C23)C=CC=C1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC=CC3=NSN=C23)C=CC=C1 GGEBRAOZEQLQSI-AWEZNQCLSA-N 0.000 description 1
- VGVUXTINZQXOOH-JTQLQIEISA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=C(NS(=O)(=O)C2=CC=CC=C2[N+](=O)[O-])C=CS1 VGVUXTINZQXOOH-JTQLQIEISA-N 0.000 description 1
- ICHATGQNZZQMAZ-INIZCTEOSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=CC(NC(=O)NC2=CC(N)=CC=C2)=CC=C1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=CC(NC(=O)NC2=CC(N)=CC=C2)=CC=C1 ICHATGQNZZQMAZ-INIZCTEOSA-N 0.000 description 1
- GRRUNXFROAUUAN-INIZCTEOSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=CC=C1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=CC(NS(=O)(=O)C2=CC=C(N)C=C2)=CC=C1 GRRUNXFROAUUAN-INIZCTEOSA-N 0.000 description 1
- LLVSGNQBGQCWMF-LBPRGKRZSA-N N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=CC=C(C2=CC=CC=C2N)O1 Chemical compound N=C(N)NCCC[C@H](NO)C(=O)C(=O)C1=CC=C(C2=CC=CC=C2N)O1 LLVSGNQBGQCWMF-LBPRGKRZSA-N 0.000 description 1
- SRMSLTYAMRQKMM-FQEVSTJZSA-N [H]OC(=O)[C@H](CCCNC(=N)N)NC(=O)C1=C(NS(=O)(=O)C2=CC=CC(CCC3=CC=CN=C3)=C2)C=CS1 Chemical compound [H]OC(=O)[C@H](CCCNC(=N)N)NC(=O)C1=C(NS(=O)(=O)C2=CC=CC(CCC3=CC=CN=C3)=C2)C=CS1 SRMSLTYAMRQKMM-FQEVSTJZSA-N 0.000 description 1
- VMXGZGLXNIIDSG-INIZCTEOSA-N [H]OC(=O)[C@H](CCCNC(=N)N)NC(=O)C1=C(NS(=O)(=O)C2=CC=CC(CCCN)=C2)C=CS1 Chemical compound [H]OC(=O)[C@H](CCCNC(=N)N)NC(=O)C1=C(NS(=O)(=O)C2=CC=CC(CCCN)=C2)C=CS1 VMXGZGLXNIIDSG-INIZCTEOSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/26—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D333/38—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/12—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by nitrogen atoms not being part of nitro or nitroso groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D307/56—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Definitions
- This invention relates to peptidomimetics which have NP-1 antagonist activity and which have activity of potential benefit in therapy.
- neuropilin-1 is a receptor for members of the VEGF family of angiogenic cytokines, particularly VEGF-A 165 , as wells as a receptor for a family of molecules called semaphorins or collapsins which play a key role in the guidance of neuronal axons during mammalian development.
- NP-1 is known to mediate the growth cone-collapsing and chemorepulsive activity of semaphorin 3A.
- NP-1 has been shown to play a role in the primary T-cell immune response.
- NP-1 may have a significant role in pathology.
- Such conditions include stroke, ischaemic eye disease, cancer and rheumatoid arthritis.
- New compounds have been discovered, which have NP-1 antagonist activity.
- the present invention is a compound of formula I or formula II
- X is CH 2 , C(O), NH, O or SO 2 ;
- Y is a direct bond or furanylene
- Z 1 is an arylene or heteroaromatic group
- Z 2 is a direct bond, a SO 2 NH, CONH or NHCONH group
- Z 3 is an aryl or heteroaromatic group
- Z 4 is CH 2 or NR 1 ;
- Z 5 is H, OH, C(O)OR 1 or P(O)(OR 1 ) 2 ;
- Z 6 is, OR 1 or NHR 2 ;
- each R 1 is independently H or an alkyl group
- each R 2 is independently H or a CN, OH or SO 2 CH 3 group
- n 0, 1 or 2
- the compound is of formula I, wherein X, Y, Z 1-6 , and R 1-2 are as defined above.
- the compounds according to the invention contain an asymmetrically substituted carbon atom.
- the presence of this asymmetric centre in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic and non-racemic mixtures thereof.
- tautomers of the specific compounds of the invention exist, and these are included within the scope of the invention. These tautomers may be formed after the formal migration of a hydrogen atom, and the switch of a single bond and an adjacent double band. Methods of tautomerization will be well known to those skilled in the art.
- alkyl refers to a straight or branched chain alkyl moiety, including for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like.
- aryl means an aromatic hydrocarbon moiety and includes phenyl, biphenyl or naphthyl group.
- the aryl ring may be substituted, for example by an NO 2 group.
- arylene means a divalent aromatic hydrocarbon moiety and includes phenylene, biphenylene or naphthylene.
- the arylene ring may be substituted, for example by an NH 2 group.
- heteromatic refers to monovalent or divalent aromatic ring systems, from which at least one ring atom is selected from the group, O, N, or S and includes for example benzofused furanyl, thiophenylene, thiophenylene (phenyl), pyridyl, indolyl, pyridazinyl, piperazinyl, pyrimidinyl, thiazolylene and the like.
- the activity of the compounds of the invention means that they may be useful in the treatment of diseases in which NP-1 may have a significant role in pathology.
- the compounds of the invention may be useful for stimulating nerve repair, for the treatment of neurodegeneration and for use in anti-cancer therapy. They may also be useful in the treatment of a disease where modulation of the immune system is required, for example, following transplant surgery.
- Yet other conditions that may be treated using a compound of the invention include skin diseases such as psoriasis, diseases requiring immunomodulation, angiogenesis in the eye, diabetes, macular degeneration, glaucoma and heart failure.
- compounds of the invention may be formulated and administered by procedures, and using components, known to those of ordinary skill in the art.
- the appropriate dosage of the compound may be chosen by the skilled person having regard to the usual factors such as the condition of the subject to be treated, the potency of the compound, the route of administration etc.
- Suitable routes of administration include oral, intravenous, intramuscular, intraperitoneal, intranasal and subcutaneous.
- a NP-1 antagonist may compete with semaphorin-3A for binding to NP-1, and thereby antagonise inhibitory effects of semaphorin-3A on axonal outgrowth and migration in nerve cells. Potential applications of this are in promoting neurite outgrowth, in stimulating nerve repair or treating neurodegeneration. Further, an NP-1 antagonist may promote the survival of semaphorin-3A-responsive neurones, an effect that would confirm or enhance its utility in the applications given above, and may extend these applications, e.g. to treating neuronal death caused by episodes of ischaemia as in stroke and some eye diseases.
- NP-1 may be essential for VEGF-induced angiogenesis in cancer, eye disease, rheumatoid arthritis and other diseases. Therefore, NP-1 antagonists may have applications in the inhibition of VEGF-dependent angiogenesis in disease.
- NP-1 antagonists may also play a role in modulating the immune system. Therefore, it may be useful to give a compound of the invention before, during or after a transplant.
- a NP-1 antagonist may compete with VEGF for binding to NP-1 in tumour cells and promote cell death in NP-1-expressing tumour cells. Potential applications of this are in anti-cancer therapy. Furthermore, a NP-1 antagonist has anti-metastatic potential since it effectively inhibits carcinoma cell adhesion to extra-cellular matrix proteins and cell migration.
- Methyl-3-aminothiophene-2-carboxylate (100-500 mg, 1 eq) was stirred with the corresponding aromatic sulfonyl chloride (1.1 eq) in pyridine (5 mL), under nitrogen, at 20° C. for 18 hours.
- Carboxylic acid (20-250 mg, 1 eq) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1.1 eq) were suspended in dichloromethane (5 mL) and the mixture was stirred at 20° C. for 10 minutes. N,N-Diisopropylethylamine (7 eq) was added to the mixture and stirred for a further 10 minutes. The appropriate amine (1.1 eq) was added and the reaction mixture was then stirred for 24-48 hours at 20° C. After this time the reaction solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL).
- the phases were separated and the aqueous phase extracted with ethyl acetate (3 ⁇ 20 mL).
- the organic phases were combined and washed with brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the crude residue.
- the Fmoc-Arg-Wang resin (typically 100 mg, 1 eq) was swollen with N,N-dimethylformamide (2 mL) for 30 minutes. The N,N-dimethylformamide was removed, piperidine in N,N-dimethylformamide (2 mL, 1:5) was added and the resin agitated for 5 minutes. The solvent was removed, and further piperidine in N,N-dimethylformamide (2 mL, 1:5) was added and agitated for a further 15 minutes. The solvents were removed and the resin was washed with dichloromethane (5 mL), methanol (5 mL), N,N-dimethylformamide (5 mL) and dried in vacuo. A Kaiser test was performed and, if positive (i.e., free amine present), the resin was deemed suitable for further transformation.
- the scaffold (3 eq), 1-hydroxybenzotriazole hydrate (3 eq) and N,N′-diisopropylcarbodiimide (3 eq) were dissolved in N,N-dimethylformamide (2 mL) and added to the resin.
- the reaction mixture was agitated for 3 hours at room temperature, however, some scaffolds were agitated for 18 hours.
- the reagents were removed from the resin and the resin was washed with dichloromethane (5 mL), methanol (5 mL), and N,N-dimethylformamide (5 mL).
- a Kaiser test was performed and, if negative (i.e., no free amine present), the resin was deemed suitable for further transformation.
- the scaffold (3 eq), 1-hydroxybenzotriazole hydrate (3 eq), and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (3 eq) were dissolved in N,N-dimethylformamide (2 mL) and added to the resin.
- N,N-diisopropylethylamine (9 eq) was added and the reaction mixture was agitated for 3 hours at room temperature, however, some scaffolds were agitated for 18 hours.
- the reagents were removed from the resin and the resin was washed with dichloromethane (5 mL), methanol (5 mL), and N,N-dimethylformamide (5 mL).
- a Kaiser test was performed and, if negative (i.e., no free amine present), the resin was deemed suitable for further transformation.
- the scaffold (3 eq), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (4 eq) were dissolved in N,N-dimethylformamide (2 mL) or dichloromethane/N-methyl-2-pyrrolidone (2 mL, 19:1) and added to the resin.
- N,N-diisopropylethylamine (9 eq) was added and the reaction mixture was agitated for 3 hours at room temperature, however, some scaffolds were agitated for 18 hours.
- the reagents were removed from the resin and the resin was washed with dichloromethane (5 mL), methanol (5 mL), and N,N-dimethylformamide (5 mL).
- a Kaiser test was performed and, if negative (i.e., no free amine present), the resin was deemed suitable for further transformation.
- the resulting resins were dried under vacuum prior to deprotection/cleavage.
- the N-terminal aniline resin (typically 100 mg, 1 eq) was washed with dichloromethane (3 ⁇ 5 mL), 4-nitrobenzene sulfonyl chloride (5 eq) was added in anhydrous dichloromethane (2 mL) followed by triethylamine (3 eq). The reaction mixture was then agitated for 16 hours at room temperature. The reagents were removed and the resin was washed with dichloromethane (2 ⁇ 5 mL), methanol (2 ⁇ 5 mL) and N,N-dimethylformamide (2 ⁇ 5 mL). A chloranil test was performed and, if negative (i.e., no free aniline present), the resin was deemed suitable for further transformation.
- N-terminal aniline resin typically 100 mg, 1 eq
- dichloromethane 3 ⁇ 5 mL
- 4-nitrophenyl isocyanate 5 eq
- dichloromethane 2 mL
- the reaction mixture agitated for 16 hours at room temperature.
- the reagents were removed and the resin was washed with dichloromethane (2 ⁇ 5 mL), methanol (2 ⁇ 5 mL) and N,N-dimethylformamide (2 ⁇ 5 mL).
- a chloranil test was performed and, if negative (i.e., no free aniline present), the resin was deemed suitable for further transformation.
- the aniline resin typically 100 mg, 1 eq
- the acid (4 eq), bromo-tripyrrolidino-phosphonium-hexafluorophosphate (4.8 eq) and 2,6 lutidine (15 eq) were stirred at room temperature for 15 minutes and added to the pre-swollen resin.
- reaction mixture was then agitated at room temperature for 24 hours to effect coupling and then washed with N,N-dimethylformamide (3 ⁇ 10 ml), N,N-dimethylformamide:N,N-diisopropylethylamine (1:1, 3 ⁇ 10 ml), further N,N-dimethylformamide (3 ⁇ 10 ml), dichloromethane (3 ⁇ 10 ml), methanol (3 ⁇ 10 ml) and diethyl ether (3 ⁇ 10 ml).
- a chloranil test for anilines was carried out and, if negative (i.e., no free amine present), the resin was deemed suitable for cleavage.
- the nitro-containing resin typically 100 mg, 1 eq
- N,N-dimethylformamide (2 mL) for 30 minutes.
- the N,N-dimethylformamide was removed, tin chloride dihydrate (10 eq) was added to the resin in N,N-dimethylformamide (2 mL) and the reaction mixture was agitated for 3 hours followed by 18 hours (with fresh reagents), at room temperature.
- the 3 and 4-aminophenyl containing resin (typically 100 mg, 1 eq) was washed with dichloromethane (2 ⁇ 5 mL).
- the aldehyde (10 eq) was added to the washed resin in a solution of acetic acid in 1,2-dichloroethane (2 mL, 98:2), the reaction mixture was agitated for 3 hours at 20° C.
- Sodium triacetoxyborohydride (20 eq) was added and the reaction mixture was agitated for 2 days at 20° C.
- the bromine containing resin typically 100 mg, 1 eq
- alkyne typically 5 eq
- copper iodide 0.2 eq
- Triethylamine was added, the reaction mixture was further degassed, tetrakis(triphenylphosphine)palladium(0) (0.1 mg) was added and the reaction mixture was stirred for 18 hours at 90° C.
- the bromine-containing resin typically 100 mg, 1 eq
- boronic acid typically 1-5 eq
- sodium carbonate (10 eq, 2M, aqueous solution) were suspended in degassed N,N-dimethylformamide:tetrahydrofuran (1:1, 4 mL).
- [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) was added and the solution further degassed.
- the reaction mixture was gently stirred at 100° C. for 18 hours.
- the peptidomimetic resin (approx. 100 mg) was washed thoroughly with dichloromethane (3 ⁇ 5 mL) and dried with nitrogen, then a solution of trifluoroacetic acid (1.9 mL), triisopropyl silane (50 ⁇ L) and water (50 ⁇ L) was added and the cleavage mixture was agitated for 90 minutes. The cleavage mixture was removed and the resin was further washed with dichloromethane (1 mL). The cleavage/dichloromethane mixtures were combined, further agitated for 90 minutes, and added drop-wise to cold diethyl ether (30 mL, ⁇ 78° C.).
- the crude final compound was dried under vacuum and purified either by elution through a 2 g C-18 column (eluent: acetonitrile/water) or by (mass-directed) preparative LC-MS using a preparative C-18 column (Phenomenex Gemini, 50 ⁇ 21.2 mm, 5 ⁇ m) and a linear AB gradient of 5-95% for B over 15 min at a flow rate of 20 mL/minute, where eluent A was 0.1% formic acid/water and eluent B was 0.1% formic acid/acetonitrile.
- the purified peptidomimetics were then lyophilized ( ⁇ 54° C., 0.08 mbar) and analysed by reverse-phase LC-MS (analytical C-18 column, Thermo Betabasic, 100 ⁇ 4.6 mm, 5 ⁇ m) and an AB gradient of 5-95% for B, over 11 minutes, at a flow rate of 1 mL/minute, where eluent A was 0.1% formic acid/water and eluent B was 0.1% formic acid/acetonitrile.
- Carboxylic acid 200-300 mg, 1 eq
- bromo-tris-pyrrolidino-phosphonium hexafluorophosphate 1.1 eq
- dichloromethane 5 mL
- N,N-Diisopropylethylamine 7 eq
- Suitably-protected amine derived from aspartic acid, 1.1 eq
- reaction solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL).
- hydrochloric acid (1M aqueous solution, 20 mL)
- ethyl acetate (20 mL)
- the phases were separated and the aqueous phase extracted with ethyl acetate (3 ⁇ 20 mL).
- the organic phases were combined and washed with brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the crude residue.
- reaction solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL).
- hydrochloric acid (1M aqueous solution, 20 mL)
- ethyl acetate (20 mL)
- the phases were separated and the aqueous phase extracted with ethyl acetate (3 ⁇ 20 mL).
- the organic phases were combined and washed with brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the crude residue.
- the desired compound was isolated as the trifluoroacetate salt.
- Carboxylic acid (20-100 mg, 1 eq) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1.1 eq) were suspended in dichloromethane (5 mL) and the mixture was stirred at 20° C. for 10 minutes.
- N,N-Diisopropylethylamine (7.0 eq) was added to the mixture and stirred for a further 10 minutes.
- Protected amine (1.1 eq) was added and the reaction mixture was then stirred at 20° C. for 16 hours. After this time the solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL).
- the phases were separated and the aqueous phase extracted with ethyl acetate (3 ⁇ 20 mL).
- the organic phases were combined and washed with hydrochloric acid (1M aqueous solution, 3 ⁇ 10 mL), brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the desired products as brown residues.
- acetylene (EG00298/5-Guanidino-2- ⁇ [3-(3-pyridin-3-ylethynyl-benzenesulfonyl amino)-thiophene-2-carbonyl]amino ⁇ -pentanoic acid; approx 10 mg) was dissolved in tetrahydrofuran:water (4:1, 2 mL), palladium on charcoal (approx 10% weight) was added and a hydrogen atmosphere introduced by balloon. The reaction mixture was stirred at 20° C. for 24 hours with occasional refilling of the hydrogen balloon. After this time the reaction mixture was filtered over CeliteTM and the solvent removed in vacuo. The yellow residue was purified using preparative LCMS.
- Porcine aortic endothelial cells expressing neuropilin-1 were cultured in Ham's F12 medium containing 10% fetal bovine serum (FBS) and 25 ⁇ g/ml hygromycin B.
- PAE cells expressing KDR were grown in Ham's F12 medium containing 10% FBS and 250 ⁇ g/ml Gentamicin G418.
- Human carcinoma cell lines (DU145, A549 and ACHN) were grown in RPMI 1640 medium containing 10% FBS and L-glutamine.
- Confluent cells in 24-well plates were washed twice with phosphate-buffered saline (PBS).
- PBS phosphate-buffered saline
- various concentrations of peptides or peptidomimetics diluted in binding medium (Dulbecco's modified Eagle's medium, 25 mM HEPES pH 7.3 containing 0.1% BSA) were added, followed by addition of 0.1 nM of 125 I-VEGF-A 165 (1200-1800 Ci/mmol, GE Healthcare).
- binding medium Dulbecco's modified Eagle's medium, 25 mM HEPES pH 7.3 containing 0.1% BSA
- the medium was aspirated and washed 4 times with cold PBS.
- the cells were lysed with 0.25 M NaOH, 0.5% SDS solution, and the bound radioactivity of the lysates was measured in a ⁇ counter. Non-specific binding was determined in the presence of 100-fold excess unlabelled VEGF-A 165 .
- Cell adhesion to extracellular matrix proteins was measured by the Innocyte ECM cell adhesion assay (Calbiochem).
- Cells were detached with a non-enzyme cell dissociation solution (Sigma), washed and resuspended in RPMI 1640 medium.
- Cells with or without peptidomimetic treatment were seeded at 3 ⁇ 10 4 cells per matrix-coated well of 96-well plates. After 1.5 h incubation, cells were washed with PBS. The attached cells were labelled with the green fluorescent dye calcein-AM and measured using a fluorescence plate reader at an excitation wavelength of 485 nm and an emission wavelength of 520 nm.
- Cell viability was determined by measurement of conversion of the tetrazolium salt XTT to form formazon dye.
- Carcinoma cells were seeded at a density of 4 ⁇ 10 3 cells per well in 96-well plates in the absence or presence of NP-1 peptide or peptidomimetic antagonists. After 44 h incubation, XTT labelling reagent mixture (Roche) was added to the cultures and they were incubated for a further 4 h. The formazon production was then measured at A 490 nm with a reference wavelength at 595 nm.
- the following compounds have an IC 50 of less than 20 ⁇ M: EG00144, EG00174, EG00203, EG00224, EG00225, EG00229, EG00264, EG00265, EG00274, EG00280, EG00283, EG00285, EG00287, EG00288, EG00291, EG00299, EG00316, EG00317, EG00318, EG00319, EG00323, EG00332, EG00350, EG00369, EG00428, EG00475.
Abstract
The present invention is a compound of formula (I) or formula (II) which are suitable as NP-1 antagonists.
Description
- This invention relates to peptidomimetics which have NP-1 antagonist activity and which have activity of potential benefit in therapy.
- A non-tyrosine kinase transmembrane protein, neuropilin-1 (NP-1) is a receptor for members of the VEGF family of angiogenic cytokines, particularly VEGF-A165, as wells as a receptor for a family of molecules called semaphorins or collapsins which play a key role in the guidance of neuronal axons during mammalian development. In particular, NP-1 is known to mediate the growth cone-collapsing and chemorepulsive activity of semaphorin 3A. NP-1 has been shown to play a role in the primary T-cell immune response.
- There are a number of conditions in which NP-1 may have a significant role in pathology. Such conditions include stroke, ischaemic eye disease, cancer and rheumatoid arthritis.
- New compounds have been discovered, which have NP-1 antagonist activity.
- According to a first aspect, the present invention is a compound of formula I or formula II
- wherein
- X is CH2, C(O), NH, O or SO2;
- Y is a direct bond or furanylene;
- Z1 is an arylene or heteroaromatic group;
- Z2 is a direct bond, a SO2NH, CONH or NHCONH group;
- Z3 is an aryl or heteroaromatic group;
- Z4 is CH2 or NR1;
- Z5 is H, OH, C(O)OR1 or P(O)(OR1)2;
- Z6 is, OR1 or NHR2;
- each R1 is independently H or an alkyl group;
- each R2 is independently H or a CN, OH or SO2CH3 group; and
- n is 0, 1 or 2,
- or a pharmaceutically acceptable salt, solvate or polymorph thereof.
- Preferably, the compound is of formula I, wherein X, Y, Z1-6, and R1-2 are as defined above.
- It will be appreciated that the compounds according to the invention contain an asymmetrically substituted carbon atom. The presence of this asymmetric centre in a compound of formula (I) can give rise to stereoisomers, and in each case the invention is to be understood to extend to all such stereoisomers, including enantiomers and diastereomers, and mixtures including racemic and non-racemic mixtures thereof.
- It will also be appreciated that tautomers of the specific compounds of the invention exist, and these are included within the scope of the invention. These tautomers may be formed after the formal migration of a hydrogen atom, and the switch of a single bond and an adjacent double band. Methods of tautomerization will be well known to those skilled in the art.
- As used in this specification, alone or in combination, the term “alkyl” refers to a straight or branched chain alkyl moiety, including for example, methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, pentyl, hexyl and the like.
- The term “aryl” means an aromatic hydrocarbon moiety and includes phenyl, biphenyl or naphthyl group. The aryl ring may be substituted, for example by an NO2 group.
- The term “arylene” means a divalent aromatic hydrocarbon moiety and includes phenylene, biphenylene or naphthylene. The arylene ring may be substituted, for example by an NH2 group.
- The term “heteroaromatic” refers to monovalent or divalent aromatic ring systems, from which at least one ring atom is selected from the group, O, N, or S and includes for example benzofused furanyl, thiophenylene, thiophenylene (phenyl), pyridyl, indolyl, pyridazinyl, piperazinyl, pyrimidinyl, thiazolylene and the like.
- The activity of the compounds of the invention means that they may be useful in the treatment of diseases in which NP-1 may have a significant role in pathology. The compounds of the invention may be useful for stimulating nerve repair, for the treatment of neurodegeneration and for use in anti-cancer therapy. They may also be useful in the treatment of a disease where modulation of the immune system is required, for example, following transplant surgery. Yet other conditions that may be treated using a compound of the invention include skin diseases such as psoriasis, diseases requiring immunomodulation, angiogenesis in the eye, diabetes, macular degeneration, glaucoma and heart failure.
- For therapeutic use, compounds of the invention may be formulated and administered by procedures, and using components, known to those of ordinary skill in the art. The appropriate dosage of the compound may be chosen by the skilled person having regard to the usual factors such as the condition of the subject to be treated, the potency of the compound, the route of administration etc. Suitable routes of administration include oral, intravenous, intramuscular, intraperitoneal, intranasal and subcutaneous.
- A NP-1 antagonist may compete with semaphorin-3A for binding to NP-1, and thereby antagonise inhibitory effects of semaphorin-3A on axonal outgrowth and migration in nerve cells. Potential applications of this are in promoting neurite outgrowth, in stimulating nerve repair or treating neurodegeneration. Further, an NP-1 antagonist may promote the survival of semaphorin-3A-responsive neurones, an effect that would confirm or enhance its utility in the applications given above, and may extend these applications, e.g. to treating neuronal death caused by episodes of ischaemia as in stroke and some eye diseases.
- Recent evidence suggests a role for NP-1 in angiogenesis. The evidence shows that NP-1 may be essential for VEGF-induced angiogenesis in cancer, eye disease, rheumatoid arthritis and other diseases. Therefore, NP-1 antagonists may have applications in the inhibition of VEGF-dependent angiogenesis in disease.
- NP-1 antagonists may also play a role in modulating the immune system. Therefore, it may be useful to give a compound of the invention before, during or after a transplant.
- In addition, a NP-1 antagonist may compete with VEGF for binding to NP-1 in tumour cells and promote cell death in NP-1-expressing tumour cells. Potential applications of this are in anti-cancer therapy. Furthermore, a NP-1 antagonist has anti-metastatic potential since it effectively inhibits carcinoma cell adhesion to extra-cellular matrix proteins and cell migration.
- The following examples illustrate the invention. General schemes for synthesising peptidomimetics of the invention are provided. Experimental detail, for both the solid and solution phase experiments, is also given.
- Ar; aromatic, Arg, Arginine; Boc, tert-butoxy carbonyl; Trt, trityl; tBu, tert-butyl; Acm, acetamidomethyl; DIC, diisopropylcarbodiimide; DIPEA, N,N-diisopropylethylamine, Et, ethyl; Fmoc, 9-fluorenylmethoxy-carbonyl; HATU, 2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HBTU, 2-(1H-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate; HetAr; Heteroaromatic, HOBt, 1-hydroxybenzotriazole; HPLC, high performance liquid chromatography; LC-MS, liquid chromatography mass spectrometry; Me, methyl; Pbf, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl; PG, protecting group; py, pyridine; PyBrOP, bromo-tris-pyrrolidino-phosphonium hexafluorophosphate; THF, tetrahydrofuran; TLC, thin-layer chromatography.
-
- Methyl-3-aminothiophene-2-carboxylate (100-500 mg, 1 eq) was stirred with the corresponding aromatic sulfonyl chloride (1.1 eq) in pyridine (5 mL), under nitrogen, at 20° C. for 18 hours.
- The reaction was monitored using TLC and, after this time, water was added to the reaction mixture (approx. 1 mL) and the solvents removed in vacuo. The resulting red/pink coloured solids were partitioned between 1M hydrochloric acid (aqueous solution, 20 mL) and ethyl acetate (20 mL). The phases were separated and the aqueous phase extracted with ethyl acetate (3×20 mL). The organic phases were combined and washed with water (25 mL), brine (saturated aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to typically afford a red/brown oily solid. The solid was then purified using flash column chromatography on silica gel (eluent ethyl acetate:iso-hexane; 25:75.
Bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1 eq) was added to a stirred solution of the aniline (1.5 mmol, 1 eq), the free acid (1.5 mmol, 1 eq) and N,N-diisopropylethylamine (3 eq) in acetonitrile (5 mL). The reaction mixture was then stirred for 20 h at 85° C. After this time the reaction solvent was removed in vacuo and the residue dissolved in ethyl acetate (15 mL).
General Procedure for the Reaction of Thiophene Amino Acids with Sulfonyl Chlorides - The amine (1 eq) was dissolved in 1,4-dioxane (7.5 mL), sodium carbonate (5 eq) was dissolved in water (7.5 mL) and the two solutions combined and stirred vigorously. Sulfonyl chloride (1.5-2.5 eq) was added, portionwise over one hour, and the brown reaction mixture stirred at room temperature for 48 hours. After this time the reaction solvent was reduced to half the volume and diluted with water (15 ml). This phase was washed with diethyl ether (15 mL) and then acidified with potassium hydrogen sulfate (10% aqueous solution). The resultant precipitate was extracted into ethyl acetate, the phases separated and the solvent removed in vacuo to afford a brown semi-solid which was purified using flash column chromatography on silica gel (eluent: ethyl acetate:iso-hexane; 50:50 increasing to methanol/ethyl acetate; 10:90) to afford the desired compound.
-
- Carboxylic acid (20-250 mg, 1 eq) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1.1 eq) were suspended in dichloromethane (5 mL) and the mixture was stirred at 20° C. for 10 minutes. N,N-Diisopropylethylamine (7 eq) was added to the mixture and stirred for a further 10 minutes. The appropriate amine (1.1 eq) was added and the reaction mixture was then stirred for 24-48 hours at 20° C. After this time the reaction solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL). The phases were separated and the aqueous phase extracted with ethyl acetate (3×20 mL). The organic phases were combined and washed with brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the crude residue.
- General Procedure for Removal of the Fmoc Group from Fmoc-Arg-Wang Resin
- The Fmoc-Arg-Wang resin (typically 100 mg, 1 eq) was swollen with N,N-dimethylformamide (2 mL) for 30 minutes. The N,N-dimethylformamide was removed, piperidine in N,N-dimethylformamide (2 mL, 1:5) was added and the resin agitated for 5 minutes. The solvent was removed, and further piperidine in N,N-dimethylformamide (2 mL, 1:5) was added and agitated for a further 15 minutes. The solvents were removed and the resin was washed with dichloromethane (5 mL), methanol (5 mL), N,N-dimethylformamide (5 mL) and dried in vacuo. A Kaiser test was performed and, if positive (i.e., free amine present), the resin was deemed suitable for further transformation.
-
- The scaffold (3 eq), 1-hydroxybenzotriazole hydrate (3 eq) and N,N′-diisopropylcarbodiimide (3 eq) were dissolved in N,N-dimethylformamide (2 mL) and added to the resin. The reaction mixture was agitated for 3 hours at room temperature, however, some scaffolds were agitated for 18 hours. The reagents were removed from the resin and the resin was washed with dichloromethane (5 mL), methanol (5 mL), and N,N-dimethylformamide (5 mL). A Kaiser test was performed and, if negative (i.e., no free amine present), the resin was deemed suitable for further transformation.
- The scaffold (3 eq), 1-hydroxybenzotriazole hydrate (3 eq), and 2-(1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (3 eq) were dissolved in N,N-dimethylformamide (2 mL) and added to the resin. N,N-diisopropylethylamine (9 eq) was added and the reaction mixture was agitated for 3 hours at room temperature, however, some scaffolds were agitated for 18 hours. The reagents were removed from the resin and the resin was washed with dichloromethane (5 mL), methanol (5 mL), and N,N-dimethylformamide (5 mL). A Kaiser test was performed and, if negative (i.e., no free amine present), the resin was deemed suitable for further transformation.
- The scaffold (3 eq), bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (4 eq) were dissolved in N,N-dimethylformamide (2 mL) or dichloromethane/N-methyl-2-pyrrolidone (2 mL, 19:1) and added to the resin. N,N-diisopropylethylamine (9 eq) was added and the reaction mixture was agitated for 3 hours at room temperature, however, some scaffolds were agitated for 18 hours. The reagents were removed from the resin and the resin was washed with dichloromethane (5 mL), methanol (5 mL), and N,N-dimethylformamide (5 mL). A Kaiser test was performed and, if negative (i.e., no free amine present), the resin was deemed suitable for further transformation. The resulting resins were dried under vacuum prior to deprotection/cleavage.
-
- The N-terminal aniline resin (typically 100 mg, 1 eq) was washed with dichloromethane (3×5 mL), 4-nitrobenzene sulfonyl chloride (5 eq) was added in anhydrous dichloromethane (2 mL) followed by triethylamine (3 eq). The reaction mixture was then agitated for 16 hours at room temperature. The reagents were removed and the resin was washed with dichloromethane (2×5 mL), methanol (2×5 mL) and N,N-dimethylformamide (2×5 mL). A chloranil test was performed and, if negative (i.e., no free aniline present), the resin was deemed suitable for further transformation.
-
- The N-terminal aniline resin (typically 100 mg, 1 eq) was washed with dichloromethane (3×5 mL), 4-nitrophenyl isocyanate (5 eq) was added in dichloromethane (2 mL) and the reaction mixture agitated for 16 hours at room temperature. After this time the reagents were removed and the resin was washed with dichloromethane (2×5 mL), methanol (2×5 mL) and N,N-dimethylformamide (2×5 mL). A chloranil test was performed and, if negative (i.e., no free aniline present), the resin was deemed suitable for further transformation.
-
- The aniline resin (typically 100 mg, 1 eq) was swollen in the minimum quantity of dichloromethane for 20 minutes, meanwhile the acid (4 eq), bromo-tripyrrolidino-phosphonium-hexafluorophosphate (4.8 eq) and 2,6 lutidine (15 eq) were stirred at room temperature for 15 minutes and added to the pre-swollen resin. The reaction mixture was then agitated at room temperature for 24 hours to effect coupling and then washed with N,N-dimethylformamide (3×10 ml), N,N-dimethylformamide:N,N-diisopropylethylamine (1:1, 3×10 ml), further N,N-dimethylformamide (3×10 ml), dichloromethane (3×10 ml), methanol (3×10 ml) and diethyl ether (3×10 ml). A chloranil test for anilines was carried out and, if negative (i.e., no free amine present), the resin was deemed suitable for cleavage.
-
- The nitro-containing resin (typically 100 mg, 1 eq) was swollen with N,N-dimethylformamide (2 mL) for 30 minutes. The N,N-dimethylformamide was removed, tin chloride dihydrate (10 eq) was added to the resin in N,N-dimethylformamide (2 mL) and the reaction mixture was agitated for 3 hours followed by 18 hours (with fresh reagents), at room temperature. The reagents were removed and the resin was washed with N,N-dimethylformamide (5 mL), 20% pyridine in N,N-dimethylformamide (5 mL), dichloromethane (5 mL), methanol (5 mL) and N,N-dimethylformamide (5 mL). A chloranil test for anilines was carried out and, if positive (i.e., free amine present), the resin was deemed suitable for cleavage. The resulting resins were dried under vacuum prior to deprotection/cleavage.
-
- The 3 and 4-aminophenyl containing resin (typically 100 mg, 1 eq) was washed with dichloromethane (2×5 mL). The aldehyde (10 eq) was added to the washed resin in a solution of acetic acid in 1,2-dichloroethane (2 mL, 98:2), the reaction mixture was agitated for 3 hours at 20° C. Sodium triacetoxyborohydride (20 eq) was added and the reaction mixture was agitated for 2 days at 20° C. The reagents were removed and the resin was washed with dichloromethane (2×5 mL), methanol, (2×5 mL), N,N-dimethylformamide (2×5 mL), and dichloromethane (2×5 mL). The resulting resins were dried under vacuum prior to deprotection/cleavage.
-
- The bromine containing resin (typically 100 mg, 1 eq), alkyne (5 eq) and copper iodide (0.2 eq) were suspended in degassed N,N-dimethylformamide and tetrahydrofuran (5 mL, 1:1). Triethylamine (5 eq) was added, the reaction mixture was further degassed, tetrakis(triphenylphosphine)palladium(0) (0.1 mg) was added and the reaction mixture was stirred for 18 hours at 90° C. After this time the resin was filtered and washed with N,N-dimethylformamide/tetrahydrofuran (1:1, 15 mL), N,N-dimethylformamide/water (2×15 mL), N,N-dimethylformamide (15 mL), dichloromethane (15 mL), methanol (15 mL) and diethyl ether (14 mL). The resulting resins were dried under vacuum prior to deprotection/cleavage.
-
- The bromine-containing resin (typically 100 mg, 1 eq), boronic acid (1-5 eq) and sodium carbonate (10 eq, 2M, aqueous solution) were suspended in degassed N,N-dimethylformamide:tetrahydrofuran (1:1, 4 mL). [1,1′-Bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with dichloromethane, approx. 5 mg) was added and the solution further degassed. The reaction mixture was gently stirred at 100° C. for 18 hours. After this time the resin was filtered and washed with N,N-dimethylformamide (15 mL), N,N-dimethylformamide/water (15 mL), N,N-dimethylformamide (15 mL), dichloromethane (15 mL), methanol (15 mL) and diethyl ether (14 mL). The resulting resins were dried under vacuum prior to deprotection/cleavage.
- General Procedure for Cleaving from Arg-Wang
- The peptidomimetic resin (approx. 100 mg) was washed thoroughly with dichloromethane (3×5 mL) and dried with nitrogen, then a solution of trifluoroacetic acid (1.9 mL), triisopropyl silane (50 μL) and water (50 μL) was added and the cleavage mixture was agitated for 90 minutes. The cleavage mixture was removed and the resin was further washed with dichloromethane (1 mL). The cleavage/dichloromethane mixtures were combined, further agitated for 90 minutes, and added drop-wise to cold diethyl ether (30 mL, −78° C.). A white solid precipitated and was pelleted by centrifugation, the diethyl ether was decanted and another portion of cold diethyl ether (20 mL) was added, thoroughly mixed, centrifuged, and decanted. This process was repeated once more. The crude final compound was dried under vacuum and purified either by elution through a 2 g C-18 column (eluent: acetonitrile/water) or by (mass-directed) preparative LC-MS using a preparative C-18 column (Phenomenex Gemini, 50×21.2 mm, 5 □m) and a linear AB gradient of 5-95% for B over 15 min at a flow rate of 20 mL/minute, where eluent A was 0.1% formic acid/water and eluent B was 0.1% formic acid/acetonitrile. The purified peptidomimetics were then lyophilized (−54° C., 0.08 mbar) and analysed by reverse-phase LC-MS (analytical C-18 column, Thermo Betabasic, 100×4.6 mm, 5 μm) and an AB gradient of 5-95% for B, over 11 minutes, at a flow rate of 1 mL/minute, where eluent A was 0.1% formic acid/water and eluent B was 0.1% formic acid/acetonitrile.
- All final compounds were isolated as trifluoroacetate salts.
- Table 1 summarises the final compounds constructed using these methods.
-
TABLE 1 ID EG00136; (S)-2-{[4′-(6- EG00144; (S)-2-{[3-(4- EG00160; (S)-2-{[2-(3- Amino-hexanoylamino)- Amino- Amino- biphenyl-4-carbonyl]- benzenesulfonylamino)- benzenesulfonylamino)- amino}-5-guanidino- thiophene-2-carbonyl]- benzoylamino]-5- pentanoic acid amino}-5-guanidino- guanidino-pentanoic pentanoic acid acid Structure ID EG00161; (S)-2-{[2-(4- EG00162; (S)-2-{[2-(3- EG00163; (S)-2-{[5-(2- Amino- Amino- Amino-phenyl)-furan-2- benzenesulfonylamino)- benzenesulfonylamino)- carbonyl]-amino}-5- benzoylamino]-5- benzoylamino]-thiazole-4- guanidino-pentanoic guanidino-pentanoic acid carbonyl]-amino}-5- acid guanidino-pentanoic acid Structure ID EG00164; (S)-2-{[5-(3- EG00165; (S)-2-[3-(3- EG00166; (S)-2-[3-(4- Amino-phenyl)-furan-2- Amino- Amino- carbonyl]-amino}-5- benzenesulfonylamino)- benzenesulfonylamino)- guanidino-pentanoic acid benzoylamino]-5- benzoylamino]-5- guanidino-pentanoic acid guanidino-pentanoic acid Structure ID EG00170; (S)-2-({5-[2-(3- EG00173; (S)-2-[3-(4- EG00174; (S)-2-{[3-(3- Amino- Aminomethyl- Amino- benzenesulfonylamino)- benzoylamino)- benzenesulfonylamino)- phenyl]-furan-2-carbonyl}- benzoylamino]-5- thiophene-2-carbonyl]- amino}-5-guanidino- guanidino-pentanoic acid amino}-5-guanidino- pentanoic acid pentanoic acid Structure ID EG00175; (S)-2-({5-[3-(4- EG00240 (S)-2-[(2- EG00185; (S)-2-{3-[3- Amino- Benzenesulfonylamino- (3-Amino-phenyl)- benzenesulfonylamino)- thiophene-3-carbonyl)- ureido]-benzoylamino}- phenyl]-furan-2- amino]-5-guanidino- 5-guanidino-pentanoic carbonyl}-amino}-5- pentanoic acid acid guanidino-pentanoic acid Structure ID EG00202; (S)-5- EG00203; (S)-2-{[3-(4- EG00224; (S)-5- Guanidino-2-{[3-(4-nitro- Acetylamino- Guanidino-2-{[3-(2- benzenesulfonylamino)- benzenesulfonylamino)- nitro- thiophene-2-carbonyl]- thiophene-2-carbonyl]- benzenesulfonylamino)- amino}-pentanoic acid amino}-5-guanidino- thiophene-2-carbonyl]- pentanoic acid amino}-pentanoic acid Structure ID EG00225; (S)-2-{[3-(2- EG00226; (S)-2-{[3-(2,4- EG00227; (S)-5- Amino- Difluoro- Guanidino-2-{[3-(2,4, benzenesulfonylamino)- benzenesulfonylamino)- 5-trichloro- thiophene-2-carbonyl]- thiophene-2-carbonyl]- benzenesulfonylamino)- amino}-5-guanidino- amino}-5-guanidino- thiophene-2-carbonyl]- pentanoic acid pentanoic acid amino}-pentanoic acid Structure ID EG00228; (S)-5- EG00229; (S)-2-{[3- EG00235; (S)-2-{[3- Guanidino-2-{[3-(toluene- (Benzo[1,2,5]thiadiazole- (2,3-Dihydro- 4-sulfonylamino)- 4-sulfonylamino)- benzofuran-5- thiophene-2-carbonyl]- thiophene-2-carbonyl]- sulfonylamino)- amino}-pentanoic acid amino}-5-guanidino- thiophene-2-carbonyl]- pentanoic acid amino}-5-guanidino- pentanoic acid Structure ID EG00260; (S)-5- EG00263; (S)-2-({3-[3-(4- EG00264; (S)-2-{[3-(5- Guanidino-2-{[3-(2- Aminobutylcarbamoyl)- Methyl- nitrobenzenesulfonylamino)- benzenesulfonylamino]- benzo[1,2,5]thiadiazole- 5-phenyl-thiophene-2- thiophene-2-carbonyl}- 5-methyl-4- carbonyl]-amino}- amino)-5-guanidino sulfonylamino)- pentanoic acid pentanoic acid thiophene-2-carbonyl]- amino}-5-guanidino- pentanoic acid Structure ID EG00265; (S)-2-{[3-(1,2- EG00266; (S)-{[3- EG00269; (S)-5- Dimethyl-1H-imidazole-4- (Benzo[1,2,5]thiadiazole- Guanidino-2-{[3-(2- sulfonylamino)- 5-sulfonylamino)- nitro- thiophene-2-carbonyl]- thiophene-2-carbonyl]- benzenesulfonylamino)- amino}-5-guanidino- amino}-5-guanidino- 5-(4-nitro-phenyl)- pentanoic acid pentanoic acid thiophene-2-carbonyl]- amino}-pentanoic acid Structure ID EG00270; (S)-2-{[3-(4- EG00271; (S)-2-{[3-(4- EG00274; (S)-2-({3-[3- Bromo-benzenesulfonylamino)- Bromo-2-methoxy- (3-Amino-prop-1-ynyl)- thiophene-2- benzenesulfonylamino)- benzenesulfonylamino]- carbonyl]-amino}-5- thiophene-2-carbonyl]- thiophene-2-carbonyl}- guanidino-pentanoic acid amino}-5-guanidino- amino)-5-guanidino- pentanoic acid pentanoic acid Structure ID EG00277; (S)-5- EG00278; (S)-2-({3-[3-(2- EG00279; (S)-5- Guanidino-2-{[3- Amino-ethylcarbamoyl)- Guanidino-2-({3-[3-(4- (naphthalene-1- benzenesulfonylamino]- [1,2,3] sulfonylamino)- thiophene-2-carbonyl}- thiadiazol-4-yl- thiophene-2-carbonyl]- amino)-5-guanidino- benzylamino)- amino}-pentanoic acid pentanoic acid benzenesulfonylamino]- thiophene-2-carbonyl}- amino)-pentanoic acid Structure ID EG00280; (S)-2-[(3-{3- EG00281; (S)-5- EG00282; (S)-2-({3-[3- [(5-Chloro-1,3-dimethyl- Guanidino-2-({3-[3-(3- (3,4-Dimethoxy- 1H-pyrazol-4-ylmethyl)- methoxy- phenylcarbamoyl)- amino]- propylcarbamoyl)- benzenesulfonylamino]- benzenesulfonylamino}- benzenesulfonylamino]- thiophene-2-carbonyl}- thiophene-2-carbonyl)- thiophene-2-carbonyl}- amino)-5-guanidino- amino]-5-guanidino- amino)-pentanoic acid pentanoic acid pentanoic acid Structure ID EG00283; (S)-5- EG00286; (S)-5- EG00287; (S)-2-{[3- Guanidino-2-[(3-{3- Guanidino-2-{[3-(5- (Benzofuran-2- [(pyridin-2-ylmethyl)- pyridin-2-yl-thiophene-2- sulfonylamino)- amino]- sulfonylamino)-thiophene- thiophene-2-carbonyl]- benzenesulfonylamino}- 2-carbonyl]-amino}- amino}-5-guanidino- thiophene-2-carbonyl)- pentanoic acid pentanoic acid amino]-pentanoic acid Structure ID EG00288; (S)-2-{[3- EG00289; (S)-5- EG00290; (S)-5- (Benzo[1,2,5]oxadiazole- Guanidino-2-{[3-(4- Guanidino-2-{[3-(5- 4-sulfonylamino)- methyl-3,4-dihydro-2H- oxazol-5-yl-thiophene- thiophene-2-carbonyl]- benzo[1,4]oxazine-7- 2-sulfonylamino)- amino}-5-guanidino- sulfonylamino)-thiophene- thiophene-2-carbonyl]- pentanoic acid 2-carbonyl]-amino}- amino}-pentanoic acid pentanoic acid Structure ID EG00291; (S)-2-{[3- EG00292; (S)-5- EG00293; (S)-5- (Benzo[b]thiophene-2- Guanidino-2-{[3-(6- Guanidino-2-({3-[3-(2- sulfonylamino)- phenoxy-pyridine-3- methyl- thiophene-2-carbonyl]- sulfonylamino)-thiophene- pyrimidin-4-yl)- amino}-5-guanidino- 2-carbonyl]-amino}- benzenesulfonylamino]- pentanoic acid pentanoic acid thiophene-2-carbonyl}- amino)-pentanoic acid Structure ID EG00294; (S)-5- EG00295; (S)-5- EG00296; (S)-2-{[3- Guanidino-2-({3-[3-(5- Guanidino-2-{[3-(5- (Benzo[1,3]dioxole-5- methyl- methyl-3-phenyl- sulfonylamino)-thiophene- [1,2,4]oxadiazol-3-yl)- isoxazole-4- 2-carbonyl]-amino}-5- benzenesulfonylamino]- sulfonylamino)-thiophene- guanidino-pentanoic thiophene-2-carbonyl}- 2-carbonyl]-amino}- acid amino)-pentanoic acid pentanoic acid Structure ID EG00299; (S)-2-{[3-(5- EG00301; (S)-5- EG00303; S)-2-{[3-(2- Bromo-2,3-dihydro- Guanidino-2-{[2-(3- Cyano-6-methyl- benzofuran-7- pyrimidin-5-yl- benzenesulfonylamino)- sulfonylamino)- benzenesulfonylamino)- thiophene-2-carbonyl]- thiophene-2-carbonyl]- thiophene-2-carbonyl]- amino}-5-guanidino- amino}-5-guanidino- amino}-pentanoic acid pentanoic acid pentanoic acid Structure ID EG00308; (S)-5- EG00309; (S)-5- EG00310; (S)-2-{[3-(3- Guanidino-2-({3-[3-(3- Guanidino-2-({3-[3-(1- Furan-2-yl- methyl- methyl-1H-pyrazol-3- benzenesulfonylamino)- 3H-imidazol-4-ylethynyl)- ylcarbamoyl)- thiophene-2-carbonyl]- benzenesulfonylamino]- benzenesulfonylamino]- amino}-5-guanidino- thiophene-2-carbonyl}- thiophene-2-carbonyl}- pentanoic acid amino)-pentanoic acid amino)-pentanoic acid Structure ID EG00314; (S)-5- EG00316; (S)-2-[(3-{3- EG00317; (S)-2-[(3-{3- Guanidino-2-{[3-(3- [(2,5-Dimethyl-2H-pyrazol- [(3,5-Dimethyl-isoxazol- thiophen-2-yl- 3-ylmethyl)-amino]- 4-ylmethyl)-amino]- benzenesulfonylamino)- benzenesulfonylamino}- benzenesulfonylamino}- thiophene-2-carbonyl]- thiophene-2- thiophene-2- amino}-pentanoic acid carbonyl)-amino]- carbonyl)-amino]- 5-guanidino- 5-guanidino-pentanoic pentanoic acid acid Structure ID EG00318; (S)-2-[(3-{3- EG00319; (S)-5- EG00320; (S)-5- [(5-Chloro-3-methyl-1- Guanidino-2-[(3-{3-[(1- Guanidino-2-[(3- phenyl-1H-pyrazol-4- methyl-1H-indazol-3- methanesulfonylamino- ylmethyl)-amino]- ylmethyl)-amino]- thiophene-2-carbonyl)- benzenesulfonylamino}- benzenesulfonylamino}- amino]-pentanoic acid thiophene-2-carbonyl)- thiophene-2-carbonyl)- amino]-5-guanidino- amino]-pentanoic acid pentanoic acid Structure ID EG00330; (S)-2-[(3-{3- EG00332; (S)-2-[(3-{3- EG00337; (S)-5- [(3,5-Dimethyl-isoxazol- [(2,5-Dimethyl-oxazol-4- Guanidino-2-[(3-{3-[(E)- 4-ylmethyl)-amino]- ylmethyl)-amino]- 2-(4-methoxy-phenyl)- benzenesulfonylamino}- benzenesulfonylamino}- vinyl]- thiophene-2-carbonyl)- thiophene-2-carbonyl)- benzenesulfonylamino}- amino]- amino]- thiophene-2-carbonyl)- 5-guanidino-pentanoic 5-guanidino-pentanoic amino]-pentanoic acid acid acid Structure ID EG00338; (S)-5- EG00340; (S)-2-{[2- EG00333; (S)-2-[(3-{3- Guanidino-2-[(3-{3-[2-(4- (Benzo[1,2,5]thiadiazole- [(1,5-Dimethyl-1H- methoxy-phenyl)-2-oxo- 4-sulfonylamino)-4,5- pyrazol-3-ylmethyl) ethyl]- dimethyl-thiophene-3- carbamoyl] benzenesulfonylamino}- carbonyl]-amino}-5- benzenesulfonylamino}- thiophene-2-carbonyl)- guanidino-pentanoic acid thiophene-2-carbonyl)- amino]-pentanoic acid amino]- 5-guanidino- pentanoic acid Structure ID EG00334; (S)-5- EG00387; (S)-2-[(3-{4- EG00298; (S)-5- Guanidino-2-[(3-{3- [(5-Chloro-1,3-dimethyl- Guanidino-2-{[3-(3- [(1,3,5-trimethyl- 1H-pyrazol-4-ylmethyl)- pyridin-3-ylethynyl- 1H-pyrazol-4- amino]- benzenesulfonylamino)- ylmethyl)-carbamoyl]- benzenesulfonylamino}- thiophene- benzenesulfonylamino}- thiophene-2- 2-carbonyl]-amino}- thiophene- carbonyl)-amino]-5- pentanoic acid 2-carbonyl)-amino]- guanidino-pentanoic acid pentanoic acid Structure ID EG00388; (S)-2-[(3-{4- EG00389; (S)-2-[(3-{4- EG00336; (S)-2-[(3-{2- [(2,5-Dimethyl-2H- [(3,5-Dimethyl-isoxazol-4- [(5-Chloro-3-methyl-1- pyrazol-3-ylmethyl)- ylmethyl)-amino]- phenyl-1H-pyrazol-4- amino]- benzenesulfonylamino}- ylmethyl)-amino]- benzenesulfonylamino}- thiophene- benzenesulfonylamino}- thiophene-2- 2-carbonyl)-amino]-5- thiophene-2-carbonyl)- carbonyl)-amino]-5- guanidino-pentanoic acid amino]-5-guanidino- guanidino-pentanoic acid pentanoic acid Structure ID EG00413; (S)-2-[(3-{4- EG00339; (S)-5- EG00361; (S)-2-[(3-{2- [(2,5-Dimethyl-oxazol-4- Guanidino-2-[(3-{3-[(5- [(4-Chloro-1-methyl-1H- ylmethyl)-amino]- methyl-isoxazol-3- pyrazol-3-ylmethyl)- benzenesulfonylamino}- ylmethyl)-carbamoyl]- amino]- thiophene-2-carbonyl)- benzenesulfonylamino}- benzenesulfonylamino}- amino]-5-guanidino- thiophene-2-carbonyl)- thiophene-2-carbonyl)- pentanoic acid amino]-pentanoic acid amino]-5-guanidino- pentanoic acid Structure ID EG00376; (S)-2-[(3-{2- EG00477; (S)-5- EG00237; (S)-2-{[5-tert- [(2,5-Dimethyl-oxazol- Acetimidoylamino-2-[2- Butyl-3-(4-methoxy- 4-ylmethyl)-amino]- (benzo[1,2,5]thiadiazole- benzenesulfonylamino)- benzenesulfonylamino}- 4-sulfonylamino)- thiophene-2-carbonyl]- thiophene-2- benzoylamino]- amino}-5-guanidino- carbonyl)-amino]- pentanoic acid pentanoic acid 5-guanidino-pentanoic acid Structure -
- Carboxylic acid (200-300 mg, 1 eq) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1.1 eq) were suspended in dichloromethane (5 mL) and the mixture was stirred at 20° C. for 10 minutes. N,N-Diisopropylethylamine (7 eq) was added to the mixture and stirred for a further 10 minutes. Suitably-protected amine (derived from aspartic acid, 1.1 eq) was added and the reaction mixture was then stirred for 2 days at 20° C. After this time the reaction solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL). The phases were separated and the aqueous phase extracted with ethyl acetate (3×20 mL). The organic phases were combined and washed with brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the crude residue.
- Table 2 summarises the compounds constructed using this method.
-
TABLE 2 ID (S)-2-{[3-(2-Nitro- (S)-2-{[3- (S)-2-{[3-(4-Nitro- benzenesulfonylamino)- (Benzo[1,2,5]thiadiazole- benzenesulfonylamino)- thiophene-2-carbonyl]- 4-sulfonyl amino)- thiophene-2-carbonyl]- amino-pentanedioic acid thiophene-2-carbonyl]- amino-pentanedioic acid 5-tert-butyl ester-1-methyl amino}-pentanedioic acid 5-tert-butyl ester-1-methyl ester 1-tert-butyl ester 5-methyl ester ester Structure -
- The appropriate side-chain carboxylic acid (50-150 mg, 1 eq) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1.5 eq) were suspended in dichloromethane (5 mL) and the mixture was stirred at 20° C. for 10 minutes. N,N-Diisopropylethylamine (9 eq) was added to the mixture and the solution stirred for a further 10 minutes. Tert-Butoxycarbonylguanidine (1.5 eq, prepared in accordance with reference 1) was added and the reaction mixture was then stirred for 20 hours at 20° C. After this time the reaction solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL). The phases were separated and the aqueous phase extracted with ethyl acetate (3×20 mL). The organic phases were combined and washed with brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the crude residue.
- Table 3 summarises the compounds constructed using this method.
-
TABLE 3 ID (S)-2-{[3- (S)-5-(tert-butoxycarbonyl)- (Benzo[1,2,5]thiadiazole- Guanidino-2-{[3-(4-nitro- 4-sulfonylamino)-thiophene- enzenesulfonylamino)- 2-carbon thiophene-2-carbonyl]- yl]-amino}-5-(tert- amino}-5-oxo-pentanoic butoxycarbonyl)-guanidino- acid methyl ester 5-oxo-pentanoic acid tert- butyl ester Structure -
- (S)-5-(tert-butoxycarbonyl)-Guanidino-2-{[3-(4-nitro-benzenesulfonylamino)-thiophene-2-carbonyl]-amino}-5-oxo-pentanoic acid methyl ester (10 mg, 0.016 mmol) was stirred with hydrochloric acid (2M aqueous solution:tetrahydrofuran; 1:1) at 80° C. for 4 hours. After this time the reaction solvent was removed in vacuo and the crude residue was purified via elution through a 2 g C-18 column (eluent: water, followed by acetonitrile:water; 20:80) to afford the desired compound, isolated as the hydrochloride salt.
-
- (S)-2-{[3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-thiophene-2-carbonyl]-amino}-pentanedioic acid 1-tert-butyl ester 5-methyl ester was stirred in dichloromethane/trifluoroacetic acid (2.5 mL, 5:1) for 16 hours at 20° C. After this time the solvent was removed in vacuo and the resulting yellow residue was purified using preparative LC-MS.
- The desired compound was isolated as the trifluoroacetate salt.
-
- (S)-5-tert-butoxycarbonyl-Guanidino-2-{[3-(2-nitro-benzenesulfonylamino)-thiophene-2-carbonyl]-amino}-5-oxo-pentanoic acid methyl ester was stirred in hydrochloric acid (1:1, 4 M aqueous solution:tetrahydrofuran) at 80° C. for 3 hours, followed by 48 hours at room temperature followed by a further 2 hours at 80° C. The solvent was removed in vacuo and the residue purified by chromatography on a 2 g C-18 column (eluent: water increasing to acetonitrile:water; 20:80) to afford the desired compound, isolated as the hydrochloride salt.
-
- 3-(2-Bromo-N-tert-butoxycarbonyl-benzenesulfonylamino)-thiophene-2-carboxylic acid methyl ester (1 eq), the boronic acid (2.5 eq) and potassium phosphate (tribasic, 2 M aqueous solution, 4 eq) were suspended in degassed 1,2-dimethoxyethane (10 mL). The solution was further degassed and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium (II) (complex with dichloromethane, 0.1 eq) added in one portion. The reaction mixture was heated at 90° C. for 4 hours. After this time the solvent was removed in vacuo and the brown residue either isolated by one of three methods:
- A: Filtration following precipitation with hydrochloric acid (1M, aqueous solution).
- B: The residue was partitioned between ethyl acetate and hydrochloric acid (1M aqueous solution). The phases were separated and the aqueous phase extracted with ethyl acetate (3×15 mL), the combined organic extracts were washed with water, brine, dried over magnesium sulfate and the solvent removed in vacuo to afford the desired compounds.
- C: Used without any further manipulation.
- All were used without further purification in subsequent reactions.
-
- The methyl ester (1 eq) was stirred with lithium hydroxide (2.53 mmol, 3-5 eq) in tetrahydrofuran/methanol/water (10 mL, 5:3:2) at 20 to 80° C. for 3 to 48 hours as necessary. After this time the organic solvent was removed in vacuo, the residue diluted to 5 mL with water and then acidified with hydrochloric acid (1M, aqueous solution, 15 mL) upon which either precipitation occurred and the product was collected by filtration and dried in vacuo; or the aqueous phase was extracted with ethyl acetate (3×10 mL) and the combined organic phases dried over magnesium sulfate and the solvent removed in vacuo to afford the desired products.
-
- The appropriately substituted 3- and 4-bromophenyl-containing carboxylic acids (50-200 mg, 1 eq), the boronic acid (2.5 eq) and potassium phosphate (tribasic, 2 M aqueous solution, 4 eq) were suspended in degassed 1,2-dimethoxyethane (10 mL). The solution was further degassed and [1,1′-bis(diphenylphosphino)ferrocene]dichloropalladium(II) (complex with dichloromethane, 0.1 eq) added in one portion. The reaction mixture was heated at 90° C. for 4 hours. The reaction mixture was heated at 90° C. for 4 hours. After this time the solvent was removed in vacuo and the brown residue isolated by one of the following methods:
- A: Filtration following precipitation with hydrochloric acid (1M, aqueous solution).
- B: The residue was partitioned between ethyl acetate and hydrochloric acid (1M aqueous solution). The phases were separated and the aqueous phase extracted with ethyl acetate (3×15 mL), the combined organic extracts were washed with water, brine, dried over magnesium sulfate and the solvent removed in vacuo to afford the desired compounds.
- All were used without further purification in subsequent reactions.
- General Procedure for PyBroP Coupling in Solution (using H-Arg(Pbf)-OtBu)
- Carboxylic acid (20-100 mg, 1 eq) and bromo-tris-pyrrolidino-phosphonium hexafluorophosphate (1.1 eq) were suspended in dichloromethane (5 mL) and the mixture was stirred at 20° C. for 10 minutes. N,N-Diisopropylethylamine (7.0 eq) was added to the mixture and stirred for a further 10 minutes. Protected amine (1.1 eq) was added and the reaction mixture was then stirred at 20° C. for 16 hours. After this time the solvent was removed in vacuo and the residue partitioned between hydrochloric acid (1M aqueous solution, 20 mL) and ethyl acetate (20 mL). The phases were separated and the aqueous phase extracted with ethyl acetate (3×20 mL). The organic phases were combined and washed with hydrochloric acid (1M aqueous solution, 3×10 mL), brine (saturated, aqueous solution, 25 mL), dried over magnesium sulfate, filtered and the solvent removed in vacuo to afford the desired products as brown residues.
- Table 4 summarises the products produced using this method.
-
TABLE 4 ID (S)-5-(2,2,4,6,7-Pentamethyl-2,3- (S)-2-({3-[4-(2-Methoxy-pyrimidin-5- dihydro-benzofuran-5-sulfonyl- yl)-benzenesulfonylamino]-thiophene- guanidino)-2-({3-[4-(1-methyl-1H- 2-carbonyl}-amino)-5-(2,2,4,6,7- pyrazol-4-yl)-benzenesulfonyl amino]- pentamethyl-2,3-dihydro-benzofuran- thiophene-2-carbonyl}-amino)- 5-sulfonyl-guanidino)-pentanoic acid pentanoic acid tert-butyl ester tert-butyl ester Structure ID (S)-2-({3-[4-(3,5-Dimethyl-isoxazol-4- (S)-2-({3-[5-(3,5-Dimethyl-isoxazol-4- yl)-benzenesulfonylamino]-thiophene- yl)-2,3-dihydro-benzofuran-7- 2-carbonyl}-amino)-5-(2,2,4,6,7- sulfonylamino]-thiophene-2-carbonyl}- pentamethyl-2,3-dihydro-benzofuran-5- amino)-5-(2,2,4,6,7-pentamethyl-2,3- sulfonyl-guanidino)-pentanoic acid tert- dihydro-benzofuran-5-sulfonyl- butyl ester guanidino)-pentanoic acid tert-butyl ester Structure ID (S)-5-(2,2,4,6,7-Pentamethyl-2,3- (S)-5-(2,2,4,6,7-Pentamethyl-2,3- dihydro-benzofuran-5-sulfonyl- dihydro-benzofuran-5-sulfonyl- guanidino)-2-({3-[5-(1-methyl-1H- guanidino)-2-({3-[5-(4-methyl- pyrazol-4-yl)-2,3-dihydro-benzofuran- 3,4-dihydro-2H-pyrido[3,2- 7-sulfonylamino]-thiophene-2- b][1,4]oxazin-7-yl)-2,3-dihydro- carbonyl}-amino)-pentanoic acid tert- benzofuran-7-sulfonylamino]- butyl ester thiophene-2-carbonyl}-amino)- pentanoic acid tert-butyl ester Structure ID 2-({3-[3-(4,4,5,5-Tetramethyl- 2-({3-[3-(Pyridin-4-yl)- [1,3,2]dioxaborolan-2-yl)- benzenesulfonylamino]-thiophene-2- benzenesulfonylamino]-thiophene-2- carbonyl}-amino)-5-(2,2,4,6,7- carbonyl}-amino)-5-(2,2,4,6,7- pentamethyldihydro-benzofuran-5- pentamethyl dihydro-benzofuran-5- sulfonyl-guanidino)-pentanoic acid sulfonyl-guanidino)-pentanoic acid tert- tert-butyl ester butyl ester Structure ID 2-({3-[3-(3,5-Dimethyl-isoxazol-4-yl)- 2-({3-[3-(2,3-Dihydro-benzofuran-5-yl) benzene sulfonylamino]-thiophene-2- benzene sulfonylamino}-thiophene-2- carbonyl}-amino)-5-(2,2,4,6,7- carbonyl}-amino)-5-(2,2,4,6,7- pentamethyldihydro-benzofuran-5- pentamethyldihydro-benzofuran-5- sulfonyl-guanidino)-pentanoic acid tert- sulfonyl-guanidino)-pentanoic acid butyl ester tert-butyl ester Structure ID 2-({3-[3-(1-methyl-1H-pyrazol-4-yl)- 2-({3-[3-(2-methoxy-pyrimidin-5-yl))- benzene sulfonylamino]-thiophene-2- benzene sulfonylamino]-thiophene-2- carbonyl}-amino)-5-(2,2,4,6,7- carbonyl}-amino)-5-(2,2,4,6,7- pentamethyldihydro-benzofuran-5- pentamethyldihydro-benzofuran-5- sulfonyl-guanidino)-pentanoic acid tert- sulfonyl-guanidino)-pentanoic acid butyl ester tert-butyl ester Structure ID 2-({3-[2-(pyrimidin-5-yl))-benzene 2-({3-[2-(1-methyl-1H-pyrazol-4-yl)- sulfonyl amino]-thiophene-2-carbonyl}- benzene sulfonylamino]-thiophene-2- amino)-5-(2,2,4,6,7- carbonyl}-amino)-5-(2,2,4,6,7- pentamethyldihydro-benzofuran-5- pentamethyldihydro-benzofuran-5- sulfonyl-guanidino)-pentanoic acid tert- sulfonyl-guanidino)-pentanoic acid butyl ester tert-butyl ester Structure ID 2-({3-[2-(3,5-Dimethyl-isoxazol-4-yl)- 2-({3-[2-(2,3-dihydro-benzofuran-5-yl) benzenesulfonylamino]-thiophene-2- benzenesulfonylamino]-thiophene-2- carbonyl}-amino)-5-(2,2,4,6,7- carbonyl}-amino)-5-(2,2,4,6,7- pentamethyldihydro-benzofuran-5- pentamethyldihydro-benzofuran-5- sulfonyl-guanidino)-pentanoic acid tert- sulfonyl-guanidino)-pentanoic acid butyl ester tert-butyl ester Structure ID 2-({3-[2-(2-methoxy-pyrimidin-5-yl))- 2-({3-[2-(pyridin-4-yl)-benzenesulfonyl benzenesulfonylamino]-thiophene-2- amino]-thiophene-2-carbonyl}-amino)- carbonyl}-amino)-5-(2,2,4,6,7- 5-(2,2,4,6,7-pentamethyldihydro- pentamethyldihydro-benzofuran-5- benzofuran-5-sulfonyl-guanidino)- sulfonyl-guanidino)-pentanoic acid tert- pentanoic acid tert-butyl ester butyl ester Structure -
- The pinacol, tert-butoxy and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl protected compound was dissolved in trifluoroacetic acid/triisopropylsilane/water (10 mL, 95:2.5:2.5), the reaction mixture was stirred at 20° C. for 2 days. The solvents were removed in vacuo and the resulting yellow residue was purified using preparative LC-MS.
The desired compound was isolated as the trifluoroacetate salt.
General Procedure for the Removal of Tert-Butyl and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-Sulfonyl Groups Using Trifluoroacetic Acid - The tert-butoxy and 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl protected compounds were dissolved in trifluoroacetic acid/triisopropylsilane/water (10 mL, 95:2.5:2.5) and the reaction mixture was stirred at 20° C. for 2 days. The solvents were removed in vacuo and the compound were purified using preparative LC-MS.
- All final compounds were isolated as trifluoroacetate salts.
- Table 5 summarises the final compounds constructed using these methods.
-
TABLE 5 ID EG00401; (S)-5-Guanidino-2-{[3-(3- EG00324; (S)-5-Guanidino-2-{[3-(2- pyridin-4-yl-benzenesulfonylamino)- pyridin-4-yl-benzenesulfonylamino)- thiophene-2-carbonyl]-amino}- thiophene-2-carbonyl]-amino}-pentanoic pentanoic acid acid Structure ID EG00425; (S)-5-Guanidino-2-({3-[4- EG00426; (S)-5-Guanidino-2-({3-[4-(2- (1-methyl- methoxy- 1H-pyrazol-4-yl)- pyrimidin-5-yl)-benzenesulfonylamino]- benzenesulfonylamino]-thiophene-2- thiophene-2-carbonyl}-amino)-pentanoic carbonyl}-amino)-pentanoic acid acid Structure ID EG00427; (S)-2-({3-[4-(3,5-Dimethyl- EG00428; (S)-2-({3-[5-(3,5-Dimethyl- isoxazol- isoxazol- 4-yl)-benzenesulfonylamino]- 4-yl)-2,3-dihydro-benzofuran-7-sulfonyl thiophene-2-carbonyl}-amino)-5- amino]-thiophene-2-carbonyl}-amino)-5- guanidino-pentanoic acid guanidino-pentanoic acid Structure ID EG00429; (S)-5-Guanidino-2-({3-[5- EG00343; (S)-2-({3-[2-(3,5-Dimethyl- (1-methyl- isoxazol-4-yl)-benzenesulfonylamino]- 1H-pyrazol-4-yl)-2,3-dihydro- thiophene- benzofuran-7-sulfonylamino]- 2-carbonyl)-amino)-5-guanidino- thiophene-2-carbonyl}-amino)- pentanoic acid pentanoic acid Structure ID EG00345; (S)-5-Guanidino-2-({3-[2- EG00346; (S)-5-Guanidino-2-{[3-(2- (1-methyl-1H-pyrazol-4-yl)- pyrimidin-5-yl-benzenesulfonylamino)- benzenesulfonylamino]- thiophene-2-carbonyl]-amino}-pentanoic thiophene-2-carbonyl}-amino)- acid pentanoic acid Structure ID EG00347; (S)-5-Guanidino-2-({3-[3- EG00349; (S)-5-Guanidino-2-({3-[3-(1- (2-methoxy-pyrimidin-5-yl)- methyl-1H-pyrazol-4-yl)- benzenesulfonylamino)- benzenesulfonylamino]- thiophene-2-carbonyl)-amino)- thiophene-2-carbonyl}-amino)-pentanoic pentanoic acid acid Structure ID EG00350; (S)-2-({3-[3-(3,5-Dimethyl- EG00475; (S)-5-Guanidino-2-({3-[5-(4- isoxazol-4-yl)-benzenesulfonylamino]- methyl-3,4-dihydro-2H-pyrido[3,2- thiophene-2-carbonyl}-amino)-5- b][1,4]oxazin-7-yl)-2,3-dihydro- guanidino-pentanoic acid benzofuran-7- sulfonylamino]-thiophene-2-carbonyl}- amino)-pentanoic acid Structure -
- The acetylene (EG00298/5-Guanidino-2-{[3-(3-pyridin-3-ylethynyl-benzenesulfonyl amino)-thiophene-2-carbonyl]amino}-pentanoic acid; approx 10 mg) was dissolved in tetrahydrofuran:water (4:1, 2 mL), palladium on charcoal (approx 10% weight) was added and a hydrogen atmosphere introduced by balloon. The reaction mixture was stirred at 20° C. for 24 hours with occasional refilling of the hydrogen balloon. After this time the reaction mixture was filtered over Celite™ and the solvent removed in vacuo. The yellow residue was purified using preparative LCMS.
-
- The acetylene (EG00274/(S)-2-({3-[3-(3-Amino-prop-1-ynyl)-benzenesulfonylamino]-thiophene-2-carbonyl}-amino)-5-guanidino-pentanoic acid; approx 10 mg) was dissolved in tetrahydrofuran:water (4:1, 2 mL), palladium on charcoal (approx 10% weight) was added and a hydrogen atmosphere introduced by balloon. The reaction mixture was stirred at 20° C. for 24 hours with occasional refilling of the hydrogen balloon. After this time the reaction mixture was filtered over Celite™ and the solvent removed in vacuo. The yellow residue was purified using preparative LCMS and the desired compound isolated as the trifluoroacetate salt.
-
- EG00229/(S)-2-{[3-(Benzo[1,2,5]thiadiazole-4-sulfonylamino)-thiophene-2-carbonyl]-amino}-5-guanidino-pentanoic acid (1.0 eq), N,N-diisopropylethylamine (9.0 eq) and HATU (2-(7-aza-1H-benzotriazole-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate, 1.5 eq) were stirred in N,N-dimethylformamide (2 mL) at 40° C. for 30 minutes. Hydroxylamine hydrochloride (1.5 eq) was added and the reaction mixture stirred at 40° C. for 16 hours. After this time the solvent was removed in vacuo and the yellow residue was purified using preparative LCMS. The desired compound was isolated as the trifluoroacetate salt.
- Described below are experimental methods for various binding and adhesion studies, which were carried out on several compounds of the invention. Results of these studies are given below.
- Porcine aortic endothelial cells expressing neuropilin-1 (PAE/NP-1) were cultured in Ham's F12 medium containing 10% fetal bovine serum (FBS) and 25 μg/ml hygromycin B. PAE cells expressing KDR (PAE/KDR) were grown in Ham's F12 medium containing 10% FBS and 250 μg/ml Gentamicin G418. Human carcinoma cell lines (DU145, A549 and ACHN) were grown in RPMI 1640 medium containing 10% FBS and L-glutamine.
- 125I-VEGF-A165 binding
- Confluent cells in 24-well plates were washed twice with phosphate-buffered saline (PBS). At 4° C. various concentrations of peptides or peptidomimetics diluted in binding medium (Dulbecco's modified Eagle's medium, 25 mM HEPES pH 7.3 containing 0.1% BSA) were added, followed by addition of 0.1 nM of 125I-VEGF-A165 (1200-1800 Ci/mmol, GE Healthcare). After 2 h of incubation at 4° C., the medium was aspirated and washed 4 times with cold PBS. The cells were lysed with 0.25 M NaOH, 0.5% SDS solution, and the bound radioactivity of the lysates was measured in a γ counter. Non-specific binding was determined in the presence of 100-fold excess unlabelled VEGF-A165.
- Cell adhesion to extracellular matrix proteins (basement membrane protein complex, laminin I, collagen IV, fibronectin or vitronectin) was measured by the Innocyte ECM cell adhesion assay (Calbiochem). Cells were detached with a non-enzyme cell dissociation solution (Sigma), washed and resuspended in RPMI 1640 medium. Cells with or without peptidomimetic treatment were seeded at 3×104 cells per matrix-coated well of 96-well plates. After 1.5 h incubation, cells were washed with PBS. The attached cells were labelled with the green fluorescent dye calcein-AM and measured using a fluorescence plate reader at an excitation wavelength of 485 nm and an emission wavelength of 520 nm.
- Cell migration was measured in chemotaxis 24-transwell plates with collagen I-coated inserts. The various concentrations of serum in RPMI 1640/0.1% BSA were placed in the bottom wells of the plates, while top inserts incorporating PET (polyethylene terephthalate) track-etched membranes with 8 micron pores (Becton Dickinson Biosciences) were placed over the bottom wells. Cells were trypsinised, washed and resuspended in RPMI 1640/0.1% BSA. 1.5×106 cells with or without peptide or peptidomimetic treatment as indicated were loaded into each top inserts, and the chemotaxis trans-well plates were incubated at 37° C. for 4 h. After the incubation, non-migrated cells on the top side of the trans-well membranes were removed, and migrated cells on the under side of the trans-well membranes were stained with the REASTAIN Quick-Diff kit (REAGENA). The stained cells from each well were counted in 4 fields at ×100 magnification using an eyepiece indexed graticule (100 grids).
- Cell viability was determined by measurement of conversion of the tetrazolium salt XTT to form formazon dye. Carcinoma cells were seeded at a density of 4×103 cells per well in 96-well plates in the absence or presence of NP-1 peptide or peptidomimetic antagonists. After 44 h incubation, XTT labelling reagent mixture (Roche) was added to the cultures and they were incubated for a further 4 h. The formazon production was then measured at A490 nm with a reference wavelength at 595 nm.
- In the cell-matrix adhesion studies, it was found that EG00144 was effective, at concentrations from 10-100 μM, at inhibiting the adhesion of DU145 cancer cells to extracellular matrix proteins.
- In the cell migration studies, it was found that EG00144 decreased migration of A549 and ACHN cells, at concentrations from 10-100 μM.
- In the cell viability studies, it was found that EG00229 reduced the viability of A549 cells, at a concentration of 100 μM.
- The following compounds have an IC50 of less than 20 μM: EG00144, EG00174, EG00203, EG00224, EG00225, EG00229, EG00264, EG00265, EG00274, EG00280, EG00283, EG00285, EG00287, EG00288, EG00291, EG00299, EG00316, EG00317, EG00318, EG00319, EG00323, EG00332, EG00350, EG00369, EG00428, EG00475.
Claims (16)
1. A compound of formula I or formula II
wherein
X is CH2, C(O), NH, O or SO2;
Y is a direct bond or furanylene;
Z1 is an arylene or heteroaromatic group;
Z2 is a direct bond, a SO2NH, CONH or NHCONH group;
Z3 is an aryl or heteroaromatic group;
Z4 is CH2 or NR1;
Z5 is H, OH, C(O)OR1 or P(O)(OR1)2;
Z6 is, OR1 or NHR2;
each R1 is independently H or an alkyl group;
each R2 is independently H or a CN, OH or SO2CH3 group; and
n is 0, 1 or 2,
or a pharmaceutically acceptable salt, solvate or polymorph thereof.
2. A compound according to claim 1 , wherein Z2 is an SO2NH group.
3. A compound according to claim 1 or claim 2 , wherein Z1 is phenylene, biphenylene, thiophenylene, -thiophenylene(phenyl), -thiophenylene(alkyl), furanylene, thiazolylene or pyridylene.
4. A compound according to any preceding claim, wherein Z3 is an aryl group.
5. A compound according to claim 4 , wherein Z3 is an -aryl(nitro) or aryl(amino) group.
6. A compound according to any of claims 1 to 3 , wherein Z3 is a benzofused 5-membered ring containing one or more heteroatoms selected from N, O or S.
7. A compound according to claim 6 , wherein Z3 is benzo[1,2,5]thiadiazole.
8. A compound according to any preceding claim for use in therapy.
9. A compound according to any preceding claim, for use in stimulating nerve repair.
10. A compound according to any of claims 1 to 8 , for use in the treatment of neurodegeneration.
11. A compound according to any of claims 1 to 8 , for use in the treatment of cancer.
12. A compound according to any of claims 1 to 8 , for use in immune system modulation.
13. A method of stimulating nerve repair, using a compound according to any of claims 1 to 7 .
14. A method of treating neurodegeneration, using a compound according to any of claims 1 to 7 .
15. A method of treating cancer, using a compound according to any of claims 1 to 7 .
16. A method of immune system modulation, using a compound according to any of claims 1 to 7 .
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/493,110 US20120269864A1 (en) | 2006-10-04 | 2012-06-11 | Arginine Derivatives with NP-I Antagonistic Activity |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0619611.7A GB0619611D0 (en) | 2006-10-04 | 2006-10-04 | Compounds and their use |
GB0619611.7 | 2006-10-04 | ||
PCT/GB2007/003766 WO2008040979A1 (en) | 2006-10-04 | 2007-10-04 | Arginine derivatives with np-i antagonistic activity |
US43952309A | 2009-09-15 | 2009-09-15 | |
US13/361,134 US8227606B2 (en) | 2006-10-04 | 2012-01-30 | Arginine derivatives with NP-1 antagonistic activity |
US13/493,110 US20120269864A1 (en) | 2006-10-04 | 2012-06-11 | Arginine Derivatives with NP-I Antagonistic Activity |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/361,134 Division US8227606B2 (en) | 2006-10-04 | 2012-01-30 | Arginine derivatives with NP-1 antagonistic activity |
Publications (1)
Publication Number | Publication Date |
---|---|
US20120269864A1 true US20120269864A1 (en) | 2012-10-25 |
Family
ID=37453962
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/439,523 Expired - Fee Related US8158789B2 (en) | 2006-10-04 | 2007-10-04 | Arginine derivatives with NP-I antagonistic activity |
US13/361,134 Expired - Fee Related US8227606B2 (en) | 2006-10-04 | 2012-01-30 | Arginine derivatives with NP-1 antagonistic activity |
US13/493,110 Abandoned US20120269864A1 (en) | 2006-10-04 | 2012-06-11 | Arginine Derivatives with NP-I Antagonistic Activity |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/439,523 Expired - Fee Related US8158789B2 (en) | 2006-10-04 | 2007-10-04 | Arginine derivatives with NP-I antagonistic activity |
US13/361,134 Expired - Fee Related US8227606B2 (en) | 2006-10-04 | 2012-01-30 | Arginine derivatives with NP-1 antagonistic activity |
Country Status (10)
Country | Link |
---|---|
US (3) | US8158789B2 (en) |
EP (1) | EP2084140A1 (en) |
JP (1) | JP2010505807A (en) |
KR (1) | KR20090060320A (en) |
CN (1) | CN101522648A (en) |
CA (1) | CA2664842A1 (en) |
GB (1) | GB0619611D0 (en) |
MX (1) | MX2009002606A (en) |
WO (1) | WO2008040979A1 (en) |
ZA (1) | ZA200901399B (en) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0914856D0 (en) * | 2009-08-25 | 2009-09-30 | Ark Therapeutics Ltd | Compounds |
KR102378975B1 (en) * | 2020-10-16 | 2022-03-24 | 건양대학교산학협력단 | Pharmaceutical composition comprising inhibitor of neuropilin-1 expression or activity for preventing or treating chronic rhinosinusitis |
WO2022127654A1 (en) * | 2020-12-16 | 2022-06-23 | 四川大学华西第二医院 | Anti-fibrosis pharmaceutical composition and application thereof |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2665898B1 (en) | 1990-08-20 | 1994-03-11 | Sanofi | DERIVATIVES OF AMIDO-3 PYRAZOLE, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM. |
JPH1059997A (en) * | 1996-08-22 | 1998-03-03 | Microbial Chem Res Found | Amythiamicin amide derivative |
JP2002505689A (en) * | 1997-06-19 | 2002-02-19 | セプレイコー インコーポレイテッド | Quinoline-indole antimicrobial agents, uses and compositions related thereto |
GB0207644D0 (en) * | 2002-04-02 | 2002-05-15 | Ark Therapeutics Ltd | Peptides and their use |
CA2534649A1 (en) * | 2003-08-01 | 2005-02-10 | Genelabs Technologies, Inc. | Bicyclic imidazol derivatives against flaviviridae |
CA2568394A1 (en) * | 2004-06-09 | 2005-12-29 | Avanir Pharmaceuticals | Heterocyclic derivatives for treatment of hyperlipidemia and related diseases |
MX2007004051A (en) * | 2004-10-07 | 2007-05-24 | Boehringer Ingelheim Int | Pi3 kinases. |
US20070249670A1 (en) * | 2004-11-09 | 2007-10-25 | Smithkline Beecham Corporation | Glycogen Phosphorylase Inhibitor Compounds and Pharmaceutical Compositions Thereof |
-
2006
- 2006-10-04 GB GBGB0619611.7A patent/GB0619611D0/en not_active Ceased
-
2007
- 2007-10-04 JP JP2009530940A patent/JP2010505807A/en active Pending
- 2007-10-04 EP EP07824022A patent/EP2084140A1/en not_active Withdrawn
- 2007-10-04 ZA ZA200901399A patent/ZA200901399B/en unknown
- 2007-10-04 KR KR1020097006651A patent/KR20090060320A/en not_active Application Discontinuation
- 2007-10-04 WO PCT/GB2007/003766 patent/WO2008040979A1/en active Application Filing
- 2007-10-04 CN CNA2007800371194A patent/CN101522648A/en active Pending
- 2007-10-04 US US12/439,523 patent/US8158789B2/en not_active Expired - Fee Related
- 2007-10-04 MX MX2009002606A patent/MX2009002606A/en not_active Application Discontinuation
- 2007-10-04 CA CA002664842A patent/CA2664842A1/en not_active Abandoned
-
2012
- 2012-01-30 US US13/361,134 patent/US8227606B2/en not_active Expired - Fee Related
- 2012-06-11 US US13/493,110 patent/US20120269864A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20120122862A1 (en) | 2012-05-17 |
GB0619611D0 (en) | 2006-11-15 |
CA2664842A1 (en) | 2008-04-10 |
US8158789B2 (en) | 2012-04-17 |
MX2009002606A (en) | 2009-04-30 |
EP2084140A1 (en) | 2009-08-05 |
KR20090060320A (en) | 2009-06-11 |
US8227606B2 (en) | 2012-07-24 |
JP2010505807A (en) | 2010-02-25 |
US20100022525A1 (en) | 2010-01-28 |
WO2008040979A1 (en) | 2008-04-10 |
ZA200901399B (en) | 2010-06-30 |
CN101522648A (en) | 2009-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20120201749A1 (en) | NP-1 Antagonists and Their Therapeutic Use | |
EP1720864B1 (en) | Benzimidazol substituted thiophene derivatives with activity on ikk3 | |
US7767706B2 (en) | Substituted aryl acylthioureas and related compounds; inhibitors of viral replication | |
CA2848561C (en) | Guanidinobenzoic acid compound | |
TWI395743B (en) | Derivatives having ppar agonist activity | |
US10556866B2 (en) | ROR gamma (RORγ) modulators | |
US20080255222A1 (en) | Pharmaceutically active benzsulfonamide derivatives as inhibitors of protein junkinases | |
US20060235024A1 (en) | Acetylinic piperazine compounds and their use as metabotropic glutamate receptor antagonists | |
US7625902B2 (en) | Imidazolidinone derivatives | |
US20060173010A1 (en) | Modulators of TNF-alpha signaling | |
JP5518905B2 (en) | Imidazo [1,2-a] pyridine as a JNK modulator | |
WO2007140117A1 (en) | Compounds and compositions as channel activating protease inhibitors | |
US20190040012A1 (en) | Ror gamma (rory) modulators | |
US9682966B2 (en) | Kappa opioid ligands | |
JP5068913B2 (en) | Pharmaceutically active sulfonyl amino acid derivatives | |
US8227606B2 (en) | Arginine derivatives with NP-1 antagonistic activity | |
US8552033B2 (en) | Inhibitors of CXCR2 | |
US7307095B2 (en) | Inhibitors of cathepsin S | |
CN115353508A (en) | 5-pyridine-1H-indazole compound, pharmaceutical composition and application | |
US20070060569A1 (en) | Azacycloalkyl substituted acetic acid derivatives for use as MMP inhibitors | |
RU2342368C2 (en) | Agonists of receptor of peptide-1, similar to glucagone, their obtaining and application | |
US20120040996A1 (en) | 3-benzofuranyl-indol-2-one derivatives substituted at the 3 position, preparation thereof, and therapeutic use thereof | |
CN108610333B (en) | Inducing MDM2 to self-degrade E3 ubiquitin ligase dimer amide micromolecule PROTACs |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: ARK THERAPEUTICS LTD, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:JIA, HAIYAN;ZACHARY, IAN;TICKNER, MICHELLE;AND OTHERS;SIGNING DATES FROM 20090302 TO 20090726;REEL/FRAME:028351/0323 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: GB06/019611.7 THERAPIES LIMITED, UNITED KINGDOM Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:FINVECTOR VISION THERAPIES LTD.;REEL/FRAME:031420/0840 Effective date: 20130417 |